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Introduction: In spite of the drastic decrease in lead exposure, the public is still exposed 
to various sources of lead which can contribute to a blood lead level toxic to human body. 
As important human organs, kidneys are very sensitive to lead exposure and the lead 
induced nephropathy has been the main topic of lead intoxication for centuries. The new 
researchers direct their efforts to establish the causal relationship between low level lead 
exposure and the subclinical alternation in renal functions. Ther efore, the identification 
of sensitive and specific early biological effects (EBE) arises as the highest goal of 
modern lead research since classical parameters have been proven useless for this purpose. 
At the meantime, the gene-environment interaction occurring between ALAD 
polymorphism and lead confers extra risk to the population with certain alleles during 
lead exposure. The attempt to identify the susceptible population to protect is of great 
public health importance.  
 
Objectives: 1) To get some insights about the distributions of ALAD polymorphisms in a 
Vietnamese population; 2) To identify and recommend sensitive and specific early 
biological effects for lead-induced impairment in renal function; 3) To identify genetic 
alleles that are susceptible to lead exposure.  
 
Materials and Methods: This is a cross-sectional study investigating a population of 
active healthy lead workers from Vietnam whose participation was totally voluntary. Out 
of a total of 323 production workers from a lead battery manufacturer, 248 individuals 
were included in the study.  
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PbB (blood lead) was chosen as exposure index. Uα1m (urinary α1-microglobulin), 
Uβ2m (urinary β2 microglobulin), URBP (urinary retinol binding protein), Ualb (urinary 
albumin), TNAG (total N-acetyl-beta-D-glucosaminidase in urine), Sα1m (serum 
α1-microglobulin), Sβ2m (serum β2 microglobulin), ALAU (urinary amino levulinic acid) 
were chosen as outcome indices. Msp & Rsa in exon 4, Rsa in exon 5 (Rsa39), HpyIV & 
HpyCH4 in intron 6, Sau3A in intron 12, which were not in linkage disequilibrium, were 
selected to represent 46 ALAD SNPs. Each participant had their genotype, exposure and 
outcome variables measured.   
 
General linear model and multiple linear regression were used to find out 1) Is there any 
difference in means of blood lead or renal parameters between genotypes of each ALAD 
SNP after adjusting for known confounders? 2) Does the increase of PbB cause the same 
increase of renal parameters across genotype subgroups within each ALAD SNP studied? 
 
Results: The population, with a mean age of 39.3 years and mean exposure duration of 15 
years, was occupationally exposed to a modest level of lead reflected by PbB (mean, 
24.39 μg/dl).   
 
The Msp allele frequencies of ALAD polymorphism were 0.959 and 0.041 for ALAD-1, 
ALAD-2 respectively, similar to the frequencies reported in other Asian populations. For 
other ALAD SNPs, this was the first epidemiological study to report their allele 
frequencies. The frequency of Rsa-1 was 0.467 and that of Rsa-2 was 0.533. Rsa39 SNP 
had 46.7% Rsa39-1 allele and 53.3% Rsa39-2 allele. The majority of HpyCH4 alleles 
were HpyCH4-1 (0.942) and the rest were HpyCH4-2 (0.058). The frequency of HpyIV-1 
was 0.852 and that of HpyIV-2 was 0.148. Sau3A-1 took 76.9% and Sau3A-2 took 23.1% 
  vii 
of all Sau3A alleles. The genotype and allele distributions followed Hardy-Weinberg 
Equilibrium for each ALAD polymorphism.  
 
Stepwise multiple linear regression models explored and quantified the relationships 
between PbB and each outcome parameter. In the models of variables representing renal 
function, PbB was the significant predictor for TNAG (p=0.004), Uα1m (p=0.043), Uβ2m 
(p=0.043) and URBP (p=0.042). TNAG seemed specific to lead exposure for two 
variables selected by the stepwise process were PbB and exposure duration, both 
measuring exposure level. PbB was also the significant predictor for ALAU (p<0.001). 
Ualb, Sα1m and Sβ2m were not correlated to blood lead. 
 
The only significant finding in GLM analysis was that the mean blood lead of Rsa39 2-2 
(26.7 μg/dl) was significantly higher than that of Rsa39 1-1 (22.8 μg/dl) and Rsa39 1-2 
(21.7 μg/dl) groups after adjustment for age, sex, BMI and exposure duration (p=0.032).  
 
Multiple linear regression aiming at the effect modification of SNPs illustrated that 
HpyCH4 could change the association of PbB with Uα1m (p=0.002), Uβ2m (p<0.001) 
and URBP (p=0.008). In respond to 1 μg/dl increase of PbB, Uα1m, Uβ2m and URBP 
increased 1.042 mg/gCr, 1.069 μg/gCr and 1.038 mg/gCr respectively for HpyCH4 1-1 
homozygotes whereas, for HpyCH4 1-2 heterozygotes, Uα1m, Uβ2m and URBP 
increased 1.009 mg/gCr, 1.012 μg/gCr and 1.009 mg/gCr, less than those for HpyCH4 
1-1.  
 
Conclusion: The distribution of classical ALAD polymorphism in Vietnamese is similar 
to the data reported for other Asian populations. This is the first time that that  the 
  viii 
distributions of Rsa in exon4, Rsa in exon 5, HpyCH4 and HpyIV in intron 6, and Sau3A 
in intron 12 are being reported.   
 
Uα1m, Uβ2m, URBP and TNAG are possible EBEs for renal function induced by lead 
exposure.  
 
The newer ALAD polymorphism, HpyCH4 SNP in intron 6, can change the function of 
lead with regard to renal function. The exonic polymorphisms Rsa in exon 4 and exon 5 
(Rsa39) can change the lead’s effect on ALAU, an intermediate product in heme 
biosynthesis pathway. These facts suggest that ALAD SNPs other than classical MSP 
ALAD polymorphism need to be considered in order to elucidate the effect of ALAD 
polymorphism on lead exposure.  
 
Multiple linear regression model searching for effect modification of ALAD 
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1.1    SCIENTIFIC PERSPECTIVE 
      In spite of the drastic decrease of lead (Pb) exposure in recent years, lead 
intoxication is still an important public health issue worldwide because of the 
ubiquitous existence of lead in the environment. In 2001, the global disease burden 
from lead-induced disease was estimated to be 0.4% of all deaths and 0.9% of 
disability-adjusted life years (WHO, 2002).  
      In response to the decrease of lead exposure, present researchers shifted their 
focus to the consequence of long-term low-level lead exposure (Muntner et al., 2003). 
The acute cases of lead intoxication, popularly seen in old days, are unlikely to 
happen in modern time. The exposure to mild or modest lead levels caused damage, 
which can usually be defined as normal by current clinical standards. The subclinical 
alternation in function and structure of human organs was hardly detected in their 
early stage during which it is still reversible. In the case of kidney, classical renal 
function parameters creatinine clearance (CCr), blood urine nitrogen (BUN) and 
serum creatinine (SCr) can only be abnormal when more than 50% of the nephrons 
are damaged (Loghman-Adham, 1997). It is always too late for medical intervention 
at this stage of disease development. Both clinical doctors and epidemiologists 
appreciated the urgent need to identify sensitive and specific early biological effects 
(EBE) indicators for renal damage caused exclusively by lead exposure. The 
successful identification of renal EBEs can enable doctors in occupational medicine to 
monitor the early change of renal function to prevent from advancing into clinical 
disease.   
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      In the area of environmental health, interest is increasing in the role of 
variations in the human genome (polymorphisms) in modifying the effect of 
exposures to environmental health hazards (often referred to as gene–environment 
interaction), which render some individuals or groups in the population more or less 
likely to develop disease after exposure. Two primary benefits of incorporating 
genetics into the existing environmental health research framework are, 1) the ability 
to detect different levels of risk within the population, and 2) greater understanding of 
etiologic mechanisms. Both offer opportunities for developing new methods of 
disease prevention (Kelada et al., 2003). Likewise, present lead study comes into a 
new era during which personal genetic profile has to be taken into account. 
      Some studies have shown that the genetic polymorphisms of 
delta-aminolevulinic acid dehydratase (ALAD), vitamin D receptor (VDR) and nitric 
oxide synthase (NOS), were able to alter the pharmaceutical dynamics of lead so as to 
change the human susceptibility to lead exposure (Wetmur et al., 1991; Smith et al., 
1995; Weaver et al., 2003), especially ALAD polymorphism, which has already 
demonstrated such gene (ALAD gene) and environment (lead exposure) interaction in 
quite a few studies (Chia et al., 2004; Alexander et al., 1998; Sithisarankul et al., 
1997). Considering the importance of ALAD enzyme in the biological kinetics of lead 
(Bergdahl et al., 1997), ALAD gene, with more than 100 single nucleotide 
polymorphisms (SNPs), is the one worth much attention from scientific community. 
The common ALAD polymorphism, Msp SNP in exon 4, is not enough to explain all 
the confusion encountered so far. More studies about ALAD polymorphisms are in 
need to advance the current understanding of gene–environment interaction and to 
identify the populations at higher risk.  
 3 
1.2    PUBLIC HEALTH PERSPECTIVE  
      For the developing countries in Southeast Asia where the rapid 
industrialization is under way, the economic development not only put more and more 
people into lead related industries like battery manufacture, but also contributed to air 
contamination which further exposed the public to the metal. In Singapore alone, it 
was estimated that 786 workers engaged in 49 companies were occupationally 
exposed to lead (Chia et al., 1993). The situation of lead exposure is supposed to be 
worse in relatively poor countries like Vietnam, because “the main environmental 
health problems are exacerbated by poverty, illiteracy and malnutrition, and include: 
indoor and outdoor air pollution, lack of access to safe water and sanitation, exposure 
to hazardous chemicals, accidents and injuries” (the Bangkok Statement; WHO 2002). 
      However, studies targeting populations from these countries were few except 
Korean and Taiwan. The International Conference on Environmental Threats to the 
Health of Children: Hazards and Vulnerability held in Bangkok, Thailand, March 
2002, have drawn some attention to the lead threat in Southeast Asia. In recognition of 
the significance of lead exposure, Ministry of Industry in Vietnam, in collaboration 
with National University of Singapore, launched this joint project to get a picture of 














1.3    HYPOTHESES  
1) The ALAD polymorphism distribution in Vietnamese is similar to Asian 
populations. 
2) Urinary concentration of low molecular weight (LMW) protein and 
lysosomes are better EBEs for early renal damage caused by lead than 
classical renal function indices. 
3) ALAD SNPs other than like Msp SNP in exon 4 (the classical ALAD 
polymorphism) are able to affect the lead toxicity with regard to renal 
function as outcome measurements.  
 
 






















1.4 OBJECTIVES   
1) To examine ALAD polymorphism distribution in a new population in Asia 
(Vietnam)  
2) To establish if there is an association between lead exposure and renal 
function reflected by urine concentration of low molecular weight protein 
and lysosome.  
3) To examine the interaction between ALAD polymorphism and lead 
exposure (gene-environment interaction) so as to identify susceptible 
ALAD alleles which confer more risk to people with these alleles during 
lead exposure  
4) To identify and recommend sensitive and specific EBEs for renal function 
impairment induced by lead exposure by seeking affirmative dose-effect 
























2.1    BACKGROUND  
      Lead is one of heavy metals that remain health threats to human beings. 
Because of the ubiquitous existence of lead in the environment, the general population 
is more or less exposed to lead. The people hired in lead related industries had an even 
higher lead exposure. Although the intensity of exposure level has decreased 
substantially in recent decades, with ever decreasing blood lead that is toxic to human 
being, the current safe standard of lead exposure was not considered safe anymore, 
especially for the populations who are specifically venerable to lead effect, for 
instance, children, women in pregnancy and the persons with susceptible genotypes.  
      With the development of molecular biology, the knowledge of genetics has 
been incorporated into the environmental health research. In the case of lead study, 
individual genetic profile has to be taken into account in investigating the toxic effect 
of lead. According to genetic theories, people with certain gene are more subject to 
some diseases than others. Likewise, the gene encoding δ-amino levulinic acid 
dehydratase (ALAD), an enzyme actively involved in lead kinetics, could make a 
portion of population with some ALAD genotype more susceptible to lead toxicity. As 
such, these people need special attention and protection. It is of public health 
importance to figure out which allele is the susceptible one and how it operates in 
human body.  
2.2    OVERVIEW OF LEAD EXPOSURE   
      In general, the lead exposure is decreasing worldwide, especially in developed 
countries such as the countries in Europe and USA. These countries launched a series 
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of initiatives and programs to reduce lead contamination. As a result, dramatic decline 
in lead concentration in blood (PbB) of general population has been achieved.  
      The large scale surveys (National Health And Nutrition Examination Survey, 
NHANES) conducted in USA evidently showed a constant decline in blood lead in 
general population as well as in subgroups by age. During the period of NHANES II 
(1976-1980, n=9832), the average blood lead levels dropped approximately 37% (5.4 
μg/dl) from 1976 through 1980 (Annest et al., 1983). Then from NHANES II to phase 
1 of NHANES III (1988-1991, n=12119), the geometric mean (GM) of PbB dropped 
78% from 12.8 to 2.8 μg/dl. The GM of PbB in children aged 1 to 5 years declined 
77% from 13.7 to 3.2 μg/dl for non-Hispanic white children and 72% from 20.2 to 5.6 
μg/dl for non-Hispanic black children. The prevalence of PbB of 10 μg/dl  or greater 
in this group declined from 85% to 5.5% for non-Hispanic white children and from 
97.7% to 20.6% for non-Hispanic black children (Pirkle et al., 1994). This declination 
continued in the years followed. The number of children with confirmed elevated PbB 
of 10 µg/dl or greater steadily decreased from 130,512 in 1997 to 74,887 in 2001 
(Meyer et al., 2003). The similar declination occurred too in Belgium, which has seen 
a decrease of median PbB from 17 to 7.8 μg/dl since 1978 until 1989 (Ducoffre et al., 
1990).  
      Lead in gasoline was a proven cause for elevation in PbB for the public and 
the effect of its removal was impressive and convincing (Pirkle et al., 1994; Bono et 
al., 1995; Annest et al., 1983). Annest et al (1983) pointed out that the main cause for 
the fall of PbB in NHANES II was the elimination of lead from gasoline which had 
happened as early as 1970s. Italy’s experience directly substantiated that the reduction 
of lead in gasoline greatly improved the quality of atmosphere and was strongly 
associated with the decline in PbB (Bono et al., 1995). The dramatic decrease in PbB 
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has been achieved in Thailand, Philippines, India, and Pakistan since they reduced 
their use of lead in gasoline in 1990s (Suk et al., 2003). In Brazil, lead was withdrawn 
from gasoline by the end of the 1980s (Paoliello and De Capitani, 2005) and the 
decline in PbB was observed.  
      In occupational settings, stringent health measures had been taken to protect 
workers from lead exposure. In Korea, the incipient efforts taken were, promoting the 
awareness of the hazards of lead exposure, monitoring zinc protoporyphin (ZPP) level 
and introducing a respiratory protection program. A computerized health management 
system was developed subsequently and lead in blood and air were measured and 
controlled. The latest measure was to monitor bone lead level. These serial efforts 
resulted in a 17.7 μg/dl decrease in mean PbB of lead workers from 1988 to 1998 (Lee, 
1999). 
      Although the exposure level kept going down in overall, human beings still 
live with various lead sources which can contribute to a toxic blood lead level. Food 
and water are main media containing lead. In USA, the food, in the place of the lead 
polluted air, became the main source of lead. In Japan, the daily lead intake for 
non-smoking women was 6.2 μg/day (GM) (Watanabe et al, 1995). In Korean, the 
geometric mean of dietary lead intake in four large cities (Seoul, Pusan, Chunan, and 
Haman) was 20.5 μg/day (Moon et al., 1995), 12% of which came from boiled rice. 
This value was 30.4 μg/day for Taiwan (Ikeda, 1995) where herbal drug consumption, 
milk consumption, drinking water, lead recycling plant made sources of lead (Liou et 
al., 1996). For Chinese, the mean of daily lead intake was as high as 86.3 μg/dl (Chen 
and Littlejohn, 1993).  
      The worse thing was that the current evidences suggested, the threshold of 
blood lead level is very low yet unknown. The PbB level of 10 μg/dl, the current safe 
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level set by CDC, USA, is not considered safe any more. As for the effect on the 
neurobehavior of children in development, there did not seem to be a threshold of PbB 
(Schwartz, 1994). Regarding renal function, positive correlation was found between 
PbB and Creatinine Clearance (CCr), Blood Urine Nitrogen (BUN) in a female 
population (n=1016) with a mean PbB below 10 μg/dl (Staessen et al., 1992).  
      In contrast to the declining trend of lead exposure, countries in Southeast Asia 
evidenced the growing exposure to lead due to rapid industrialization and urbanization 
going on in the region (Suk et al., 2003). One of byproducts of the prosperity is the 
deterioration of air quality. Based on the data on lead concentration in air and dusts 
dating back to 1980, Dr. Mohmood Khwaja reported that the lead exposure increased 
over time in Pakistan, which was supposedly attributed to leaded petrol use (Khwaja, 
2002).  
2.3    TOXIC KINETICS OF LEAD  
      Lead kinetics can be roughly divided into 3 steps, uptake from outside lead 
sources, distribution among human systems and clearance from human body. Out of 3 
steps is the lead distribution the most important step for the effect of lead mainly 
depends on the amount available to the individual organs.  
2.3.1   Uptake of Lead 
      Lead enters human body mainly through ingestion and inhalation, the two 
channels playing predominant roles in most of exposure situations. Many factors can 
affect the efficiency of absorption.  
2.3.1.1  Inhalation  
      Inhalation is the major channel for the entry into human body of lead air which 
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is present in the ambient air primarily in 
the form of aerosol. The amount of lead 
absorbed and the rate of absorption 
depend on the deposition-removal 
process, which is affected by the 
physicochemical properties of the aerosol, 
the ventilatory activity of the lung and the 
anatomic structures of the respiratory 
tract. The diameter of the particles 
determines the sites where they can reach 
and the movements they take. 
      Figure 2.1 illustrates the 3 
movements taken by particles when they 
enter the lung, a) gravitational 
sedimentation, granule with more than 5 
um in diameter b) Inertial impaction, 2-5 
um in diameter c) Diffusion or Brownian movements. 1-2 um or blow in diameter.  
      As a natural protective reaction, lead deposited in the lung will be cleared out 
by mucociliary clearance. Mucociliary cells carry the discharge containing lead from 
lower compartment of lung to upper respiratory tract, then most of it will be 
expectorated and a small part will be swallowed into the gastrointestinal tract.   
      There is a curvilinear relationship between lead concentration in air and blood 
lead illustrated in Figure 2.2.  
Figure 2.1: lead particles in lung 
          (Nicola et al, 1995) 
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2.3.1.2  Ingestion 
      For lead contained in food items, ingestion is the major channel for its entry 
into human body. Lead in air can get into digestive system through the swallowing of 
bronchial secretions. Nonfood items make additional lead sources for children who 
will pass through a phase of oral exploration. Breast-fed babies are possibly exposed 
to the lead from their mother (Ryu et al., 1978).   
      Intestinal absorption of lead, which seems to be a capacity-limited process 
(Aungst and Fung, 1981), mainly occurs in the small intestine (Conrad and Barton, 
1978). The percentage of intestinal absorption is generally low, 8.5 - 13.7% 
(Rabinowitz et al., 1976), yet has a huge inter individual variability ranging from 11% 
to over 60% (Blake, 1976). It appeared to be independent of the amount of lead 
ingested (Conrad and Barton, 1978).  
      The subject’s age, fasting conditions, gastrointestinal emptying, the chemical 
forms of lead compounds and nutritional deficiencies are capable of affecting the 
efficiency of lead uptake through ingestion. Absorption rate is higher in newborn 
animals and babies than in adult subjects. In adults, absorption rate once was reported 
to be 10%, (Rabinowitz et al., 1976) whereas this value turned out to be 42% in 
children (Ziegler et al., 1978). The rats of 5-7 days old retained more lead (53.4%) in 
blood than adult rats (10%) 80 hours after fed with lead milk (Kostial et al., 1971).  
Figure 2.2: Relationship between air lead and blood lead (Snee, 1982) 
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      Fasting considerably enhances lead absorption. A dramatic increase of 
absorption rate was seen in a study about fasting (Rabinowitz et al., 1980). Starved 
rats had a 3-4 timer higher lead absorption rate than rats with a full stomach. (Aungst 
et al., 1981) 
      Nutrition (calcium, iron, vitamin D et al) play an important role in 
toxicokinetics and toxicodynamics of lead. Animal studies demonstrated that rats 
eating lower dietary calcium got a PbB 2-3 times higher controls and they also 
manifested pronounced toxic effects of lead (Six and Goyer, 1970). The inverse 
correlation between Ca intake and lead retention was reported in children too (Ziegler 
et al., 1978). The effect of iron is somewhat controversial. Some scientists noted that 
people with low iron store demonstrated a 2-3 times higher lead uptake than that of 
normal individuals (Watson et al., 1980), while others demonstrated that intestinal 
lead absorption was independent of the body iron store (Flanagan et al., 1982). 
Vitamin D, responsible for the regulation of Ca metabolism, can regulate the 
absorption of lead. Animal studies illustrated that vitamin D administration was an 
enhancement of intestinal Pb absorption (Smith et al., 1978; Mykkanen and 
Wasserman, 1982). In return, lead exposure alters the vitamin D metabolism with the 
observation that the children whose PbB was more than 29μg/dl had significantly 
reduced vitamin D levels than the children with PbB less than 29μg/dl (Rosen et al., 
1980).   
2.3.1.3  Other Channels   
      Lead absorption through skin is not a significant route for lead entry. The only 
occasion where percutaneous absorption may be of concern is that the large areas of 
skin was contaminated with lead seen in some industries, especially when the skin is 
not intact so as to lose its protective function. Lead can pass through the placenta to 
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get into fetal circulation from maternal circulation (Goyer, 1990), exposing the fetus 
to the lead.  
2.3.2   Distribution and Retention of Lead 
      The lead distribution in human body is a very complicated process. Several 
mathematical models have been put forward in an attempt to get an in-depth 
understanding. An age-specific model proposed by Leggett is widely accepted to 
describe the pharmaceutical dynamics of lead in human body (Leggett, 1993a). 
According to the model, all human tissues can be roughly divided into 3 
compartments. Compartment one encompasses blood and some soft tissues, 
containing about 2 mg lead with a mean life of 35 days. The lead stays about 40 days 
on average in compartment two that contains 0.5-1 mg Pb in soft tissues and 
trabecular bone. Compartment three is composed mainly of cortical skeleton where 
the majority of body lead stays with a median half-time of 5.6 years (Nilsson et al., 
1991).  
      It must be bear in mind that models can only approximate the lead exchange 
among compartments under stable exposure status at which the lead intake, 
distribution and excretion have achieved a balance after certain period of time.  
      Figure 2.3 is an illustration roughly showing the toxicokinetics of lead in 
human system. It is based on a multi compartmental model including blood, soft 
tissues, two bone pools, lung and digestive tract.   
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Taking all relevant factors into account, physiological distribution of Pb 
should be described by analyzing separately blood, soft tissues and bone tissue  
2.3.2.1  Distribution of lead in blood  
      At most exposure status, more than 99% of total lead in blood is associated 
with the erythrocytes shown by both animal (Willes et al., 1977; Domanski and 
Trojanowska, 1980) and human studies (Campbell et al., 1984). Plasma may contain 
roughly 1-2% of blood lead for a wide range of exposure levels (deSilva, 1981). It 
was estimated to be 0.2% at blood lead concentration of 10 μg/dl and 2% at PbB of 
100 μg/dl (Manton and Cook, 1984). The amount of lead in plasma is tiny yet of 
considerable toxicological interest because it is in immediate equilibrium with the 
extravascular fluid and is involved in all the movements of lead between different 
biologic compartments.  
      Either in erythrocytes or in plasma, the main form of lead presence is 
protein-lead complex. Previously, it was believed that hemoglobulin is the main lead 
Figure 2.3: Toxicokinetics of Lead (Bert et al., 1989)  
 15 
binding component in human erythrocytes (Barltrop and Smith, 1975), especially 
hemoglobulin A2 (Ong and Lee, 1980). Nowadays, ALAD is proven to be the 
principal protein to bind lead in red blood cells (Bergdahl et al., 1997).  
      The intimate connection between plasma and RBC predicts the correlation 
between plasma lead and blood lead. It is agreed that the PbP does not remain 
constant but are directly correlated to blood lead values. Studies showed that there is a 
curvilinear relationship between PbP and PbB (deSilva, 1981) 
2.3.2.2  Distribution of lead in soft tissues 
      Lead is widely but unevenly distributed in all the soft tissues of the body with 
the higher lead concentrations found in the kidneys and the liver, the highest lead 
content in bone (Barry, 1975). The retention of lead in human organs after a certain 
period depends on the specific rate of lead deposition and its removal from these 
organs.   
      Lead can be rapidly incorporated into the kidney and liver (Conrad and Barton, 
1978) however, the loss of lead is a two component process, an initial rapid loss (1-7 
days regardless of organ) followed by the successive slow phase (67 days for liver and 
27 days for kidney on average) (Torvik et al., 1974).  
      The males usually had higher lead concentration than females in liver, kidney 
and brain cortex (Barry and Mossman, 1970). In many soft tissues, lead concentration 
decreased significantly with age (Schroeder and Tipton, 1968). While in bone, the 
lead retention increases with age up to the age of 40-60 years, then declined in a slow 
irregular pattern from 60-80 years (Barry and Mossman, 1970).   
2.3.2.3  Distribution of lead in Bone 
      During bone growth and at all stages of bone remodeling, lead is able to 
substitute for calcium in bone and becomes incorporated into osseous crystal. The 
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accumulation of lead in bone is a faster process than its removal (Keller and Doherty, 
1980), which is a long-term process determined by the turnover rate of bone 
(Rabinowitz et al., 1976). 
      Skeleton has two types of bone tissues, trabecular bone and cortical bone, 
defined by their turnover rate and calcium (Ca) content. Cortical bone has a slower 
turnover and higher calcium content (20-25%) than trabecular bone (5-10%). 
Corresponding to two types of bone tissues, studies found two lead removal phases 
from bone, a fast one (t1/2=1.2 years) and a slow one (t1/2=16 years) (Nilsson et al., 
1991). Therefore, lead in compact bone, where the removal of lead is extremely slow, 
may represent an inactive lead store (Keller and Doherty, 1980).  
      Lead deposited in bone can be released into the blood during the bone 
remodeling process taking place throughout our lifetime. The release of lead also 
occurs in normal physiological (pregnancy, menopause, senile osteoporosis) (Goyer, 
1990; Tsaih et al., 2001; Silbergeld et al., 1988) and pathological conditions 
(demineralization of bone tissue due to fractures or immobility), bringing about 
abundant lead in circulation. As a result, the subject has a secondary exposure to 
endogenous lead, which may lead to toxic PbB levels and signs of biological effects. 
2.3.3  Lead Excretion and Body Lead Burden  
      Fecal and urinary excretions are primary routes for lead elimination. The lead 
clearance through saliva, sweat and breast milk is negligible. The renal handling of 
lead is a complex action involving glomerular ultrafiltration and tubular function. 
Ionic lead in plasma can pass freely through the glomerular barrier to undergo 
subsequent tubular reabsorption and/or secretion. For the lead bound to proteins, 
glomerular filtration depends on the size and electrical charge of the lead-protein 
complex. However, the urinary excretion of lead began soon after absorption of the 
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element and was only in part correlated to exposure levels (Hursh and Mercer, 1970). 
The main outlet of lead excretion through the feces is bile (Klaassen and Shoeman, 
1974). Lead may form a complex with certain biliary proteins and then it is excreted 
into the bile by active transport mechanism in the liver (Castellino et al., 1966).  
      The body lead burden represents the total content of lead in the whole body at 
certain time point.  
      It has been shown that the cumulative lead retention clearly exceeds the total 
excretion of this metal. The amount of lead retained in the body increased over time 
(Barry and Mossman, 1970). Lead retention is decided by exposure type. A recent or 
short-lived lead exposure gives rise to an increase in PbB. In the case of prolonged 
exposure, the PbB increase is light while there is a significant accumulation of lead in 
the skeleton. A high proportion of lead is retained in the skeleton (about 95%, subject 
to exposure type) and, to a lesser degree, in soft tissues (about 5%) (Barry, 1975). In 
general, adult males have higher total lead retention than adult females (162.2 mg vs 
112.5 mg) (Barry and Mossman, 1970).  
2. 4    INDICES FOR LEAD EXPOSURE  
2.4.1   Lead Concentration In Blood (PbB, μg/dl) 
      The concentration of lead in whole blood (PbB) so far is the best indicator for 
lead exposure. The level of PbB expresses the equilibrium existing between lead 
absorption, retention, body stores and excretion, in short, an index for the internal 
dose. PbB values may assume different patterns of stability in accordance with 
exposure situations (Benson et al., 1976; Shannon and Graef, 1992). 
      At most time, PbB only represents the recent a few weeks’ exposure for the 
mean life of lead in blood is around 35 days (Rabinowitz et al., 1976) or even as short 
as 5 days assuming there is no lead transferred from bone into circulation (Leggett, 
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1993b).  
      Including demographic characteristics (age, sex, race), personal habits 
(smoking, drinking, general sanitation), socioeconomic status (family income, 
occupation, education), and environment (type of building, degree of 
industrialization), a great number of covariates can affect the variation of PbB,  
      PbB is an age-related index. It reaches a peak in the populations under the age 
of 5, and then reduces gradually to a minimum around 13-15 year and increases 
around the age of 50-60. A slow progressive decline follows in the end (Huel et al., 
1986; Kawai et al., 1987; Mahaffey et al., 1982; Quinn, 1985). In general, there is a 
positive correlation between PbB and age in adult populations (Jakubowski et al., 
1996; Yang et al., 1996; Brody et al., 1994).    
      Gender is another determinant of PbB level. Under similar exposure level, 
men tend to get higher PbB than women. The discrepancy was found to be slight (3%) 
and insignificant from childhood up to the age of 12 and gradually increased to reach 
maximum levels of 30-35% at age of 30-40 (Huel et al., 1986; Quinn, 1985). Recent 
studies looking at relatively lower lead exposure level solidify this opinion (Brody et 
al., 1994; Jakubowski et al., 1996). The sex-related difference in PbB has been 
ascribed to the disparate exposure status with regard to working activity, smoking and 
drinking habits (Liou et al., 1996; Morisi et al., 1992). The roles of metabolic, 
endocritic and constitutional factors played in lead distribution are also of remarkable 
concern.  
      Smoking has long been known as a vital covariate of PbB. Smoking is 
positively associated with lead with varying strength (Leroyer et al., 2001; Cerna et al., 
1997; Jakubowski et al., 1996; Liou et al., 1996; Yang et al., 1996). Consumption of 
cigarette is proven to be an enhancement of blood lead (Berode et al., 1991; Morisi et 
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al., 1992; Quinn, 1985; Grasmick et al., 1985). The general trend is that current 
smokers always have a significantly higher PbB than ex-smokers and non-smokers. 
The distinction between ex-smokers and non-smokers is not so huge. The reasons 
underlying are, 1) compared to non-smokers, smokers have extra lead exposure from 
cigarettes that contain lead (Watanabe et al., 1987); 2) the hand to mouth action 
associated with smoking increase the possibility of lead contact.  
      Just like smoking, drinking is another personal habit that greatly improves the 
value of PbB. In a Danish study (n=6437, 2883 men and 3554 women), the 
consumption of alcohol was associated with an increase in PbB which remains 
significant regardless of smoking habits (Grasmick et al., 1985). The studies carried 
out in US showed that drinkers had higher blood lead for both male and female 
(Quinn, 1985; Berode et al., 1991). This increased PbB may be ascribed to the extra 
lead from wine and alcohol (Morisi et al., 1992). The alternative explanation is that 
alcohol can change the function of kidneys so that the lead metabolism will be 
affected.  
      People from different ethnic groups are thought to have different PbB. 
NHANES II revealed a statistically significant association between PbB and ethnic 
group. Black people have a higher PbB than white people (Pirkle et al., 1994). Studies 
from different areas also reported that race is a active factor in the determination of 
PbB. (Chia et al., 1991; Liou et al., 1996)  
      Industrialization was found to be positively associated with PbB. Studies 
carried out in various countries proved that people living in highly industrialized area 
tended to have higher PbB (Ducoffre et al., 1990; Cardia et al., 1989; Paoliello and De 
Capitani, 2005; Liou et al., 1996). It is understandable because environmental 
contamination due to car emission and lead related industries always increases during 
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industrialization. The higher concentrations of lead in air or dust were observed in 
cities in comparison with countryside (Grandjean, 1993; Liou et al., 1996; Paoliello 
and De Capitani, 2005).  
      PbB is very responsive to the change of outside exposure. Its interaction with 
quite a few factors makes PbB an informative index. Plus the growing accuracy and 
sensitivity of blood lead measurement. In view of all these characteristics, PbB is the 
most valuable lead parameters for epidemiological study.  
      On the other hand, these covariates are capable of biasing the results to such a 
great extent that they become confounders to be adjusted for in the analysis. It is 
absolutely necessary to do so if PbB is chosen as exposure index. Even if you take 
bone lead or chelatable lead, these covariates still need to be taken into account 
because of the close correlation between PbB, Pb-bone and Pb-Ch.  
2.4.2   Lead Concentration In Bone (Pb-Bone, μg/g)  
      Pb-bone is a reliable index of cumulative lead absorption for long-term 
exposures for two reasons. 1) the accumulation of lead in bone tissue is age-dependent: 
it begins during fetal bone development and continues to the age of 50-60 years, 
determining a progressive increase in metal levels in both trabecular and compact 
bone (Barry and Mossman, 1970); 2) whether environmental or occupational exposure, 
over 95% of the total lead body burden is deposited in the skeleton for adults (Barry, 
1975). Nuclear techniques (X-ray fluorescence) developed in the middle 1990s enable 
us to assess bone lead concentration in vivo, offering one more advantage to this 
parameter. In practice, tibia is usually sampled for cortical bone lead measurement. 
Patella and vertebrae are used to represent the trabecular bone.  
      Bone lead levels are usually higher in men than in women (Drasch et al., 1987; 
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Silbergeld et al., 1988), who may have a limited exposure to airborne lead since they 
spend much of their time at home (Silbergeld et al., 1988). The difference may also be 
the result of different food intake by gender and to personal habits such as drinking 
and smoking (Drasch et al., 1987).  
2.4.3   Other Lead Indices 
      Chelatable Lead (Pb-Ch) is measured as the total Pb excreted following 
chelation treatment. Chelatable lead indicates the amount of lead that can be 
mobilized from the body stores (Lee et al., 1995). It is thought to represent the total 
biologically active lead that is ready for exchange and action. Lead concentration in 
teeth, urine and hair are still in use in some studies. They each have critical 
shortcomings in terms of accuracy, sensitivity and reliability. Special care must be 
taken when one interprets the results from studies using these parameters.  
      The exposure indices are presented in the following figure (Figure 2.4). 
 
 
 Figure 2.4: Biomarkers of lead exposure (Sakai, 2000)  
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2.5    THE RENAL EFFECT OF LEAD  
2.5.1   Anatomy and Physiology of Kidneys 
      The pair of kidneys is the main 
organ in human urologic system. It is also 
an important link in the metabolism of 
almost all substances. The main functions 
of kidneys include, 1) Regulation of the 
water and electrolyte, 2) Retention of 
substances vital to the body, such as protein 
and glucose, 3) Maintenance of acid/base 
balance, 4) Excretion of waste products, water soluble toxic substances and drugs, 5) 
Endocrine functions comprising the secretion of erythropoietin (EPO), calcitriol (the 
active form of vitamin D) as well as the enzyme rennin.  
      Although two kidneys represent only about 0.5% of the total weight of the 
body, they receive 20–25% of the total arterial blood pumped by the heart. About 1% 
of the blood flow goes to the medulla and 99% goes to the cortex where it meets 
countless nephrons. Every minute about 20% of renal plasma flow is filtered, equal to 
a velocity of 125 ml/min. This is the normal filtration capacity called glomerular 
filtration rate (GFR).  
      In nephrons, toxic substances or metabolites are filtered out and useful 
substances are kept. Then clean blood comes back to circulation system through renal 
vein. The final product, urine, passes out of human body through tubule system 
(Figure 2.5).   
      There are three steps in the formation of urine, first simple filtration, followed 
by selective and passive reabsorption of glucose and some proteins, and then the final 
Figure 2.5: Structure of Kidney  
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step, excretion (Figure 2.6). Filtration takes place through the semi-permeable walls 
of the glomerular capillaries that are almost impermeable to proteins and large 
molecules like albumin and immunoglobulin. But small molecules like amino acid, 
ions can easily pass through the wall. Then the stream flows into proximal tubules 
where 60% of all solute, including 100% of glucose and amino acids, 90% of 
bicarbonate, 80-90% of inorganic phosphate and water, is absorbed by either active or 
passive transport. Later the fluid is concentrated at the Loop of Henlen if necessary. 
The final part of nephron, distal tubule and collecting duct, can absorb a large quantity 
of water depending on the presence of antidiuretic hormone (ADH).   
  
      Apart from the filtration-reabsorption mechanism described above, an 
auxiliary mechanism called tubular secretion is also involved. Both hydrogen ions 
(H+) and potassium ions (K+) are secreted directly into the fluid within the distal and 
collecting tubules.  
2.5.2   Physiological Basis of Lead Toxicity 
      It has been demonstrated that when lead is present in a sufficient concentration, 
it can interact with any biologic structure and function. In light of this statement, an 
unlimited number of cell functions may be affected. Any structural protein, transport 
Figure 1.6: Anephron and its working 
Figure 2.6: Physiology of Nephoron  
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system, receptor or enzyme is potentially susceptible to the toxic action of lead. 
Therefore, the toxic action of this metal depends largely on its extra and/or 
intracellular availability.  
      Cellular toxicity of lead can be summarized into three categories, 1) its 
interaction with components of cell membranes like structural proteins, transport 
systems (Na-K adenosine triphosphatase) and receptors (Weiler et al., 1988); 2) its 
effect on calcium homeostasis, (Verity, 1990) enzymatic systems and peroxideslead 
secondary to the combination with proteins in the cytosol; 3) the structural and 
functional changes of the mitochondria (Walton and Buckley, 1977).  
      Lead is known to affect the renal system, nervous system, the cardiovascular 
system, reproductive system, endocrine system and gastrointestinal system. For the 
purpose of this dissertation, I will only be concentrated on the renal system. 
2.5.3   Pathophysiology of Lead Induced Renal Injury  
      Kidneys are major organs targeted by the lead because of their involvement in 
the metabolism of the metal. In renal tubule system, ionic lead, which can be readily 
filtered out from the plasma into urine, is taken in by proximal cells back to the 
circulation. The major renal effect of acute lead poisoning therefore is the disruption 
of proximal tubular architecture which is supported by laboratory evidence (Nolan 
and Shaikh, 1992; Landrigan, 1989). The direct lead absorption from the blood to 
renal cells accounts for a small part of total lead in kidney. At this stage, histological 
changes include eosinophilic intranuclear inclusions in proximal tubular cells 
consisting of lead-protein complexes, and mitochondrial swelling (Vyskocil et al., 
1989). The renal manifestations are usually reversible after chelation therapy and 
cessation of lead exposure (Goyer, 1989). 
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      With the exposure continuing, nuclear inclusion bodies become less common 
as renal tubular atrophy and interstitial fibrosis increase in severity. During this stage, 
asymptomatic renal azotaemia and reduced glomerular filtration rate are always 
observed due to interstitial fibrosis and the damage become irreversible. If no 
effective medical intervention is administered. renal neoplasia, adenocarcinoma or 
chronic renal failure will occur (Goyer, 1989). Prolonged lead exposure also interferes 
with distal tubular secretion of urate, leading to hyperuricemia and gout. Finally, 
chronic lead exposure may cause hypertension, resulting from vasoconstriction due to 
the action of lead on the renin-angiotensin system (RAS) and on calcium signaling 

































Figure 2.7: Consequences of excessive lead exposure (Loghman-Adham, 1997) 
 
 26 
2.5.4   Renal Effect of Lead (Epidemiological Studies)  
      Lead induced nephropathy has been a medical topic for centuries. Although 
results from epidemiologic studies varied by the specific population and exposure 
type in individual studies, the dose-effect and dose-response relationships between 
lead exposure and renal damage were well established and documented. 
      With the falling exposure level of lead in environmental and occupational 
settings, chronic renal injury due to long-term lead exposure came into being the 
major environmental health concern. Chronic renal injury is a progressive and 
insidious process. When classical parameters indicted the disease, renal damage is 
always irreversible so that chelation therapy will be of no help (Chia et al., 1995a; 
Price, 1992). Under such circumstances, researchers and occupational medicine 
doctors are faced with the task of seeking early biological effects (EBE) for renal 
function at lead exposure. Compared to the classical indices, the ideal EBEs are 
supposed to show abnormality earlier and at the reversible stages of the development 
of nephropathy.  
      There are two major categories of indices that represent kidney functions. One 
category is to examine the renal glomerular filtration rate that is related to the 
glomerular integrity. It includes the blood concentration of urea nitrogen (BUN), the 
concentration of creatinine in serum (SCr), measured or calculated creatinine 
clearance (CCr), and blood uric acid (UA) (Loghman-Adham, 1997). In clinical 
practice, these parameters are commonly used for diagnosis and treatment. To 
facilitate the understanding, they are referred to as classical renal parameters in this 
thesis. The other category is to examine the integrity and function of tubule cells viz. 
proximal tubule or distal tubule. The main parameters are the urinary concentrations 
of low molecular weight (LMW) protein, urinary α1 microglobulin (Ua1m), urinary 
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β2 microglobulin (Uβ2m), urinary retinol binding protein (URBP) and lysosome 
enzyme, total N-acetyl ß-d-glucosaminidase (TNAG).  
      Bernard and Lauwerys (1989) stated that lead nephropathy in adults, even at 
an advanced stage (decreased GFR), cannot be detected by determination of low (β2 
microglobulin) or high (albumin) molecular weight proteins in urine (Bernard and 
Lauwerys, 1989). However, Loghman-Adham (1997) believed that renal changes 
induced by chronic low-level lead exposure are subtle and not reflected by changes in 
routine renal function tests such as SCr and CCr, unless more than 50% of kidney 
function is lost (Loghman-Adham, 1997). Parameters in which category or exactly 
which test can serve as ideal EBE is still a question remaining unclear. 
2.5.4.1  Classical renal parameters and associated studies 
Introduction of classical renal parameters 
      Creatinine clearance (CCr) is an index for glomerular filtration rate (GFR) by 
measuring the clearing rate of creatinine from the blood. Creatinine is a waste product 
of muscle metabolism and is produced at a constant rate proportional to the muscle 
mass of the individual, which fluctuates very little. Because it is recycled, all of the 
creatinine filtered will be excreted in the urine, making CCr an exclusive 
measurement of GFR. For adult people under 40 years old, normal results of CCr are 
90-139 ml/min for males and 80-125 ml/min for females respectively. For people over 
40, the values decrease by 6.5 ml/min for each decade of life.  
      Serum creatinine test (SCr) measures the levels of creatinine in blood. If 
kidneys function normally, the concentration of creatinine in the plasma remains 
relatively constant. Liver has little influence on creatinine metabolism. Therefore an 
elevated SCr is a useful indication of impaired kidney function. The normal SCr 
values are 0.8-1.2 mg/dl for males, and 0.6-0.9 mg/dl for females.  
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      Blood urea nitrogen test (BUN) is a measurement of the amount of nitrogen 
contained in the urea, a waste product of protein metabolism. Urea is formed in the 
liver, then filtered and excreted in the urine by the kidneys. High BUN can indicate 
kidney dysfunction; however, BUN is also affected by protein intake. The test needs 
to be done in the morning when individual’s stomach is empty. The normal BUN 
value is within 8-20 mg/dl irrespective of gender. 
Epidemiological studies  
      The studies on the effect of environmental lead exposure strongly supported 
the use of classical parameters as outcome variable. In normative aging study (NAS), 
a 744-subject subpopulation had a mean PbB of 8.1 μg/dl. After adjusting for age, 
BMI and use of diuretic and analgesic medications, a rise in PbB of 10 μg/dl was 
associated with a decrease in creatinine clearance of 10.4 ml/minute (Payton et al., 
1994). In a longitudinal study on 459 males randomly selected from the participants 
of NAS, PbB was found to be positively and significantly associated with concurrent 
SCr (p=0.005) after adjusting for age, BMI, smoking, alcohol consumption, 
educational level and hypertension. A 10-fold increase in PbB predicted an increase of 
0.08 mg/dl in concurrent serum creatinine. This association was consistent in analysis 
for the subjects with PbB below 40 μg/dl (n=452), 25 μg/dl (n=428), and 10 μg/dl 
(n=141) (Kim et al., 1996).  
      The positive correlations between PbB on the one hand, BUN and SCr on the 
other hand, have been found in a study conducted in Taiwan. Further regression 
analysis revealed that an increment of 10 μg/dl PbB produced an increase of 0.62 
mg/dl in BUN(Wang et al., 2002).  
      Staessen et al (1992) investigated the effect of environmental lead exposure 
with a population consisting of 1016 women and 965 men. The geometric mean of 
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PbB was 11.4 μg/dl for men and 7.5 μg/dl for women. ZPP was also measured as an 
indirect exposure index. Measured CCr was inversely correlated with PbB and ZPP in 
the men and the women both before and after adjustment for age, BMI and diuretic 
treatment. A 10-fold increase in PbB was associated with a reduction of 10-13 ml/min 
in CCr (Staessen et al., 1992) 
      One study investigating the dose-response relationship between lead exposure 
and renal function was in the favor of classical parameters. The authors reported that 
SCr was a significant prognostic indicator of mortality. SC values greater than 1.7 
mg/dl were likely to result in a 3-times greater risk of death from lead related disease 
(Shulman, 1989).  
      The findings from occupational lead study provided opposite evidences. A 
study in South Korean (Weaver et al., 2003a) on 803 exposed subjects and 135 
controls with the measurement of SCr, BUN, CCr (measured and calculated), URBP, 
TNAG found that, although PbB, Pb-Tibia were significantly higher in exposed group 
(GM, PbB, 32 μg/dl; Pb-Tibial, 37.2 μg/g) than control group (GM, PbB, 5.3 μg/dl; 
Pb-Tibia, 5.8 μg/g), only BUN achieved significant difference between two groups 
after adjustment. Age was found to be an effect modifier for lead’s exertion on SCr, 
CCr and BUN. In 3 multiple linear models, higher exposure indices were associated 
with worse renal functions (lower BUN, SCr and lower CCr) in old subjects, yet the 
opposite associations were observed in young subjects. Authors proposed that the 
associations in young subjects were due to hyperfiltration as happened in early stages 
of diabetes and sickle cell diseases, which will be ensued by the progressive reduction 
of GFR (Weaver et al., 2003a).   
      Dated back to a study on 76 lead workers and 68 strictly matched controls 
reported in 1994, not only there was not a decrease in CCr for exposed group 
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compared to control group, given the fact that PbB and Pb-Tibia for exposed subjects 
were all 3 times those for controls (exposure group (GM): PbB, 43 μg/dl , Pb-Tibial, 
66 μg/g; control group (GM): PbB, 14.1 μg/dl , Pb-Tibial, 21 μg/g), but also baseline 
CCr and stimulated CCr were positively correlated with Pb-Tibia (Roels et al., 1994). 
Hyperfiltration was supposed to account for the non-significance. Hyperfiltration 
seemed to be a necessary phase in the development of nephropathy induced by 
occupational lead exposure for it also occurred on two separate occasions (Hu, 1991; 
Gerhardsson et al., 1992). At most time it greatly masked the glomeruli damage and 
made glomeruli parameters insufficient to show abnormality. 
      In summary, whether a correlation between exposure indices and classical 
renal parameters can be observed in a particular study largely depends on the 
exposure type. For a large population with environmental lead exposure, a significant 
relationship can be expected. But for populations with occupational lead exposure, the 
correlation might be covered by the occurrence of hyperfiltration. Comparing to the 
occupational study in which mean PbB is normally higher than 40 μg/dl, the 
environmental exposure is a low level lead exposure with a mean PbB below 15 μg/dl. 
But it is the environmental exposure that caused significant deterioration of renal 
functions. This may offer the evidence that the pathway for occupational exposure and 
environmental exposure is totally different.  
2.5.4.2  Tubular parameters and associated studies  
      Bernard and Lauwerys (1989) reviewed 5 studies and concluded that urinary 
concentration of low or high molecular weight proteins were not able to detect lead 
nephropathy in adults, even at an advanced stage. However, 4 of the 5 studies 
reviewed were dealing with a sample less than 30 subjects (Bernard and Lauwerys, 
1989).  Other researchers stated that classical parameters measuring excretory 
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functions could have been within normal ranges despite considerable impairment of 
renal function (Price, 1992; Bauer et al., 1982) because of the great reserve capacity 
of the kidney. So the parameters measuring proximal cell integrity came up as 
alternative renal function indices.  
Introduction of tubular parameters 
      The concentration of α-1 microglobulin in urine (Uα1m): Alpha-1 
microglobulin (α1m) is synthesized in liver and pancreas and then transported to other 
human tissues. It is a lipoprotein with molecular masses between 40 kDa and 50 kDa. 
Alpha-1 microglobulin appears in a series of isoforms in plasma and other organs like 
liver, kidney, lung and heart. The reference value for the urinary concentration of α-1 
microglobulin (Uα1m) is <13.26 mg/gCr (Everaert et al., 2000). There is not normal 
reference interval of the concentration a1m in serum as yet. One study found that the 
mean concentration of Sa1m was 2.13 mg/dl in 20 healthy Japanese (Endo et al., 
1993).  
      Beta-2 microglobulin (β2m) is a 100 amino acid peptide found on the surface 
of many cells. B2m is normally filtered out of the blood by the kidney's glomeruli, 
only to be partially reabsorbed back into the circulation when it reaches the kidney's 
tubules. In glomerular kidney disease, the glomeruli are unable to filter it out, so β2m 
levels increases in the blood and decrease in the urine. In tubular kidney disease, the 
tubules can't reabsorb it back into the blood, so urine levels rise and blood levels fall. 
Therefore, β2m levels in serum and urine can work together to differentiate 
glomerular and tubular dysfunction (Tolkoff-Rubin et al., 1988). The normal reference 
level suggested for serum concentration of β2m (Sβ2m) is 1.1-2.4 mg/l 
[http://www.aruplab.com/guides/ug/tests/0080053.jsp July 25, 2005]. Urinary 
concentration of β2m (Uβ2m) is usually less than 300 µg/g Cr or 160 µg/L in healthy 
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people [http://www.aruplab.com/guides/μg/tests/0080432.jsp May 13, 2005]. The 
variation of β2m is not specific to renal disorders. Its production increases in 
inflammatory reactions and in active chronic lymphocytic leukemia. (Tolkoff-Rubin et 
al., 1988) 
      Retinol binding protein (RBP) is the protein carrying vitamin A (retinol) in 
blood. The level of RBP in blood is directly proportional to vitamin A concentrations. 
RBP can be filtered into tubule system freely because its molecular weight is only 
21,200D, less than the maximum molecular size permeable for renal glomerulus. 
Once it enters renal tubule system, RBP will be absorbed by proximal tubular cells. 
Therefore serum concentration of RBP has nothing to do with renal function. Yet the 
urine concentration of RBP (URBP) is mainly determined by the reabsorption ability 
of proximal tubular cells because overproduction of RBP does not occur at most time. 
Normal 95% reference interval for URBP was found to be 4.42-108 μg/gCr (Beetham 
et al., 1985).  
      N-acetyl-beta-D-glucosaminidase (NAG) is an important enzyme in the 
lysosomes where it serves as a catalyst in the breakdown of glycoproteins. NAG is 
present in almost all human issues with the highest found in proximal tubular cells of 
kidneys (Endo et al., 1990). The molecular weight NAG is 150,000 D, so that the wall 
of glomeruli is impermeable to NAG molecule (Price, 1992). The total NAG in 
normal urine (TNAG), caused by normal exocytosis and pinocytotic activity of the 
epithelial cells, is generally negligible. The TNAG specifically represent the renal 
tubule damage, especially proximal tubular cells (Endo et al., 1990). NAG activity is 
not significantly affected by sex or circadian rhythms. Plus, NAG is stable in urine 
that guarantees the reliability of this index (Price, 1992). All these properties add to 
advantages of TNAG as a good EBE for lead toxicity.  
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Epidemiological studies 
      In a small study (n=46) conducted in Japan (Endo et al., 1990), TNAG showed 
a significant correlation with PbB, urine lead and urine coprotoporphyrin. Later on, 
Chia et al (1994) reported a correlation between heat stable NAG and the recent 
change in concentration of PbB based on a study on 128 lead workers. It was 
concluded that the increase in TNAG activity in urine is a form of acute response to a 
sharp increase in renal burden of lead (Chia et al., 1994). One study found a good 
linear regression of NAG on PbB with 10 μg/dl PbB predicting an 14% increase of 
TNAG (Verberk et al., 1996). In some studies, TNAG was the only parameter related 
to lead exposure (Cardenas et al., 1993; Verberk et al., 1996).   
      The tricky problem with TNAG is that it is a confirmed EBE for Cadmium 
exposure. Quite a few lead researches showed that TNAG was associated with 
exposure index of Cadmium instead of lead index (Weaver et al., 2003a; Roels et al., 
1994).  
      Since TNAG might just be a sharp response to lead change, and in some 
studies, its variation was merely ascribed to the cadmium exposure, other low-weight 
molecule may act as better EBE for lead exposure. The first one discussed is urinary 
α-1 microglobulin (Uα1m). Alpha-1 microglobulin has a molecular weight three times 
higher β2m, and 10,000 Da higher than RBP. It will appear in the urine before β2m 
and RBP because the absorbing efficiency at proximal tubules is inversely related to 
the molecular weight during competition for binding sites among proteins (Chia et al., 
1995a). Clinically, the elevation of Ua1m precedes a decrease of CCr in patients with 
renal tubular disorders (Kusano et al., 1985). Alpha-1 microglobulin is freely filtered 
by the glomeruli and is stable at urine of low ph (Kido et al., 1985). Taken these 
evidences together, Uα1m can serve as a valuable EBE for renal damage.  
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      Chia et al (1995) reported that, out of Uβ2m, URBP, Ua1m and Ualb, Ua1m 
was the only parameter that showed significance between exposure and control group. 
Uα1m also showed a dose-response and dose-effect relationship with PbBint, a 
cumulative exposure index derived from serial PbB measurements, in lead workers 
(Chia et al., 1995a). Another study in Japan measured three outcome parameters, 
Ua1m, Sa1m and SCr in 99 lead workers. After dividing the sample into 5 groups by 
PbB, Ua1m was the only one that indicated a positive dose-effect association with 
PbB. Sa1m and SCr were the same across 5 groups (Endo et al., 1993). 
      The concentration of β2m in blood or urine in some studies was used to 
represent early impairment in renal function. In one animal study, the increased 
excretion of β2m in urine was the first parameter observed before glucose, total 
proteins and lysozyme (Vyskocil et al., 1989). Chia et al (1995) investigated a group 
of lead workers (n=137). An index representing long-term exposure, time-integrated 
PbB, was found to be a significant predictor for Sβ2m, Sa1m and urinary albumin. 
The fact that all 15 subjects with abnormal Sβ2m were found in the highest PbBint 
group suggested a dose-response relationship between PbBint and Sβ2m (Chia et al., 
1995c).  
      One study in 1995 looking into the relationship between blood lead and URBP, 
Uβ2m, Ualb and TNAG studied children from two polluted schools and one control 
school. The children from the polluted area showed a significant elevation of urinary 
RBP, which paralleled the value of PbB and lead in dust (Bernard et al., 1995). The 
geometric means of URBP were 73.8, 109.4 and 117.8 for clean area, polluted area 1 
and polluted area 2 respectively. URBP was the only parameter significantly related to 
PbB in a step-wise regression model. Unlike URBP, mean Uβ2m of children from 
area polluted most was not higher than that of control (66.4 to 60.3 μg/g Cr), so was 
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TNAG (1.46 to 1.56 U/g Cr) (Bernard et al., 1995). 
      In a well-designed study aiming to find out the functional and structural 
integrity of proximal tubule cell in occupationally exposure workers, the authors 
found increased Uα1m and TNAG among lead-exposed workers in comparison with 
non-exposed workers regardless of their smoking status (EL Safty et al., 2004) 
2.5.4.3  Comparisons between classical parameters and tubular parameters 
      In spite of some contradictory evidence, classical renal parameters definitely 
are not ideal early biological effects, especially under occupational exposure 
circumstances. The question is that, are tubular parameters good enough to be EBEs?  
      An integrated database was once used to assess the utility of biomarkers to 
detect nephron-toxicity. It was found that TNAG, intestinal alkaline phosphatase (IAP), 
brush border antigen and urinary low-molecular-weight proteins are generally most 
sensitive renal tests for the early detection of nephropathy. These tests all precede 
signs of clinical renal disease (e.g., elevated serum creatinine levels). In the case of 
lead exposure, TNAG and IAP are most sensitive ones (Taylor et al., 1997).  
      One study found that although all three exposure indices measured (PbB, 
Pb-Tibia, and Pb in urine) for exposure group were three times those for control group. 
Comparing the geometric means of CCr, SCr, Sβ2m, Ualb, Uβ2m and URBP between 
the two groups failed to find any significant difference (Roels et al., 1994). The only 
difference was the concentration of total NAG in urine, which might be due to 
co-exposure to Cd because TNAG was correlated with Cd concentration in urine 
instead of PbB or Pb-Tibial. The authors concluded that blood lead less than 70μg/dl 
will not cause any renal injury with regard to parameters measured in this study.  
      The study purposely designed to identify the appropriate EBEs for lead 
toxicity recruited 41 exposed and 41 control workers. Battery of tests capable of 
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detecting biochemical alteration, functional deficits and cell damage were measured 
and compared between two groups (Cardenas et al., 1993). The average PbB in 
exposed group was 48 μg/dl and that for control group was 16.7 μg/dl. But the 
significant difference was only observed in 6-keto-PGF, thromboxane and TNAG, 
which was associated with urinary concentration of CdU. Uβ2m, URBP and Ualb 
were neither significantly higher in exposure group nor correlated with concurrent 
PbB measures. Ua1m was not measured in this study (Cardenas et al., 1993).  
      Renal tubular parameters have their individual weakening point. The most 
sensitive test among EBEs appears to be urinary excretion of TNAG (Endo et al., 
1990; Chia, 1995). However, TNAG is a confirmed EBE for Cadmium exposure and 
the exposure to Cadmium is quite popular in occupational setting (Roels et al., 1994). 
Beta-2 microglobulin can be degraded in urine with PH less than 6, making the 
measurement of Uβ2m unreliable (Bernard et al., 1987). The Sβ2m and Uβ2m have a 
two-way change depending on which part of the kidney is affected whereas lead 
exposure usually exerts on both tubule and glomeruli simultaneously. Although RBP 
and α1m are stable in urine, they don’t sound very sensitive to the renal damage 
shown by the past researches. 
      One common shortcoming with all tubular tests is that they are nonspecific 
and can be abnormal during the exposure to other nephrotoxins, especially Cadmium. 
Ua1m can be elevated in cadmium-induced tubular disorders (Chia et al., 1992). 
Uβ2m and URBP have been suggested as renal indicators in cadmium research 
(Taylor et al., 1997). Most lead studies so far failed to satisfactorily rule out the 
confusing effect from co-exposure to cadmium.  
      The relationship of the urinary excretion of low molecular weight proteins or 
TNAG to subsequent development of renal failure remains to be determined (Nuyts et 
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al., 1991). Whether such small changes in renal function will result in clinically 
significant health problems is uncertain. 
      So far, it is difficult to deciding which category of renal indices are better 
EBEs for lead toxicity. Anyway, the toxic effect of lead depends on the parts in kidney 
which it affects and the intensity. Thus there may not be universal EBEs for lead 
toxicity. Pergande et al (1994) have ever suggested that the combination of urinary 
TNAG and Uα1m was useful in the early detection of lead-induced tubular changes 
(Pergande et al., 1994). Parameters measuring the biochemical alteration seemed to be 
more sensitive than tubular enzymes (Taylor et al., 1997) and their utility deserves 
more research.  
2.6    ERYTHROPOIETIC SYSTEM AND ALAD ENZYME 
2.6.1   Disturbance of Erythropoietic System 
      After lead is absorbed into the blood stream, most of it gets into red blood 
cells (RBCs) and combines with proteins inside, which are functional enzymes critical 
in heme synthesis. The combination results in the inhibition of the activity of three 
enzymes in the biosynthetic pathway, 5-aminolevulinic acid dehydratase (ALAD), 
coproporphyrinogen oxidase (COPRO-O) and ferrochelatase (FERRO-C), giving rise 
to the depletion of haem synthesis. However clinical anemia was rarely seen at current 
exposure level because of the compensation made by marrow. 
      What important to lead study about the disturbance of erythropoietic system is 
the abnormal blood and urine concentrations of haem precursors, viz aminolevulinic 
acid (ALA) and zinc protoporphyrin (ZPP). ALA is synthesized in mitochondria from 
one glycine and one succinyl-CoA catalyzed by ALA synthetase (ALAS). Then two 
ALA are condensed to form one molecule of porphobilinogen (PBG) by ALAD in 
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cytosol. The inhibition of ALAD activity by lead will cause the decrease in heme 
production which subsequently activates ALAS, resulting in the overproduction of 
ALA.  
      The ALA concentration in urine (ALAU) was introduced to monitor lead 
exposure in 1950s. ALAU is sensitive and specific to the alteration of PbB, and the 
correlation coefficient of PbB and ALAU is always above 0.7 (Sakai, 2000). A good 
dose–effect and dose-response relationship between PbB and ALAU have been 
established, thus, besides as an outcome variable for erythropoietic system, ALAU 
can be used as an exposure index for lead.  
      The last step of heme synthesis, the incorporation of a Fe ion into the molecule 
of protoporphyrin catalyzed by ferrochelatase, is also disrupted by lead by means of 
inhibiting the ferrochelatase and reducing Fe availability. When the Fe ion is not 
readily available, ferrochelatase binds the zinc ion into protoporphyrin, producing 
zinc protoporphyrin (ZPP). ZPP will accumulate in erythrocytes and its concentration 
in erythrocytes is used as exposure as well as outcome index just like ALAU.  
2.6.2   ALAD Enzyme 
      Delta-aminolevulinic acid dehydratase (ALAD) catalyzes the second step in 
the biosynthesis of heme, the condensation of two molecules of 5-aminolevulinic acid 
into porphobilinogen (PBG). ALAD has a molecular weight of 280 kDa (Dent et al., 
1990) and is composed of eight identical subunits, which each bind an atom of zinc. 
ALAD is found in the cytosol of cells where cytochrome synthesis takes place. 
Significant enzymic activity is observed in bone marrow, liver, kidney, brain and 
spleen (Moore et al. 1985).  
      In place of zinc, lead binds to –SH groups present at the active site of ALAD 
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and to those on the critical points of the molecule. The combination prevents the 
enzyme from linking with its substrate and slows down or stops the subsequent 
reactions. The negative feed-back regulation trigged by intermediate heme products 
might too play a role in the inhibition of ALAD (Inorganic lead).  
      The importance of ALAD in lead study is that it is the main lead-binding 
protein inside erythrocytes.   
      Identifying the major protein that binds lead is crucial to understand the lead 
toxicity. Previously, human studies suggested that the majority of lead in erythrocyte 
was bound to hemoglobulin in the form of lead-hemoglobulin complex and the rest 
was loosely bound to red cell membrane (Barltrop and Smith, 1975; Barltrop and 
Smith, 1972). The subsequent studies further found that the main lead binding 
component was hemoglobulin A2 (HbA2) (Ong and Lee, 1980). This opinion was 
popular until the middle or later 1990s. However, new laboratory results began to 
challenge this belief.  
      As early as 1982, Sakai proposed that ALAD might be responsible for an 
appreciable proportion of the lead-binding in red blood cells (RBCs) (Sakai et al., 
1982). In a study on protein-bound lead in RBCs (Bergdahl et al., 1997), three lead 
peaks appeared at retention times corresponding to apparent molecular masses of 240 
kDa, 45 kDa and 10 kDa or less, respectively. Fractions collected from the major peak 
(molecular masses of 240 kDa) showed ALAD activity, accounting for 35-81% of 
total lead in blood. The major peak disappeared when ALAD was extracted from the 
sample, thereby confirming that the lead was bound to ALAD (Bergdahl et al., 1997). 
This study reached a conclusion that the principal lead-binding protein in erythrocytes 
was, in fact, ALAD other than hemoglobin, because the latter has a molecular weight 
of 64 kDa. The other two peaks were unlikely to be caused by 
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hemoglobin-bound-lead, (Bergdahl et al., 1998). The protein corresponding to the lead 
peak of 45 kDa was suspected to be pyrimidine-5-nucleotidase (P5N). The protein 
with molecular mass of 10 kDa or below might be the acyl-Coa-binding protein 
(ACBP)(Bergdahl et al., 1998). A model based on the above findings predicted that 
the maximum capacity of lead binding in erythrocytes would be about 300 μg/dl, 
corresponding to a PbB of 150 μg/dl or so.  
      Lead mainly binding to ALAD instead of hemoglobin provides an explanation 
for a number of phenomena observed in lead toxicity: 1) The inhibition of ALAD 
activity was a sensitive and specific effect of lead. 2) The binding of lead to a protein 
less abundant than hemoglobin, provides an explanation of the curvilinear relation 
between PbB and PbP. The curvature can be described by a model based on limited 
binding capacity for lead-binding proteins (Bergdahl et al., 1998; O'Flaherty et al., 
1996). 3) A genetic polymorphism in ALAD gene has been suggested to make certain 
individuals be more sensitive to lead toxicity than others (Astrin et al., 1987; Wetmur 
et al., 1991a; Sithisarankul et al., 1997). The considerable binding of lead to ALAD 
may play an important role in the mechanism behind the influence of the ALAD 
polymorphism on lead toxicity. 
2.7    ALAD GENE AND ITS POLYMORPHISM 
2.7.1   Basics of Genetic Polymorphism 
      In deoxyribonucleic acid (DNA), the sequence of 4 types of bases (adenine 
(A), thymine (T), guanine (G), and cytosine (C)) contains the information that spells 
out instructions for making all of the proteins in an organism. Gene is a segment of 
DNA sequence that encodes a specific protein. The region in a gene that contains the 
code for producing the gene's protein is designated exon. In contrast to exon, the 
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noncoding sequence of a gene is called intron, which will be spliced out of the final 
transcript. 
      Mutation is a change or alteration of bases occurring in the DNA. The 
majority of mutations are copying errors during the DNA duplication from one 
generation to another. The mutation can happen anywhere in DNA regardless of intron 
or exon. In fact the overall mutation rate in exons is much less than that in introns due 
to the far longer length of the latter. The mutation resulting in an alteration of the 
encoded amino acid is defined as nonsynonymous mutation. For a synonymous 
mutation or a silent mutation the substitution causes no amino acid change to the 
protein it produces.  
      Genetic polymorphism is the one of the consequences of mutation. 
Polymorphism is coined to describe the fact that the gene occupying the same locus 
on homologous chromosomes has two or more alternate forms (allele) that are 
mutually exclusive to one another and govern the same biochemical and 
developmental process. To be called polymorphism, the frequency of each allele 
should be at least 1 percent in the population and usually unharmful. Essentially being 
a mutation, the polymorphism can happen anywhere in a gene. The one happens to the 
intron is called intronic polymorphism and that happens to the exon is called exonic 
polymorphism.  
      Single Nucleotide Polymorphism (SNP) is the most simple form and most 
common source of genetic polymorphism in the human genome (90% of all human 
DNA polymorphisms). SNP is in substance a point mutation, substitution of single 
base. A purine (A, G) replacing a purine is called transition. If a purine (A, G) is 
replaced by a pyrimidine (C, T) or vice-versa, the mutation is called transversion. 
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      Restriction enzymes are proteins that bind to a DNA molecule at a specific 
sequence and make a double-stranded cut at that sequence. They can cut a gene at 
precise points producing a collection of DNA fragments of precisely defined length. 
Because SNPs generally create a sequence legible to a specific restriction enzyme, 
restriction enzymes are utilized popularly to detect SNPs. The SNPs discovered by 
restriction enzymes can also be designated as Restriction Fragment Length 
Polymorphism (RFLP) after the name of the enzyme cutting it.   
2.7.2   ALAD Gene and ALAD Polymorphism  
      The human ALAD gene maps on chromosome 9 at 9q33.1 (Figure 2.8). It 
covers 15.01 kb from 113243145 to 113228136 on the reverse strand. There are 14 
introns and 24 exons reported in ALAD gene so far 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=gene&a=








Figure 2.8: Structure of ALAD gene  
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ALAD gene was first found polymorphic in 1981 (Battistuzzi et al., 1981). The first 
ALAD polymorphism was a SNP in exon 4 detected with Msp restriction enzyme. Since 
then, more and more SNPs in ALAD have been reported to National Center for 
Biotechnology Information (NCBI). Up to now there are 105 SNPs in total submitted to 
NCBI website (http://www.ncbi.nlm.nih.gov/SNP/).  
      Modern molecular biology holds that whether intronic or exonic polymorphisms, 
they can equally change the biochemical property of the gene product without the obvious 
alteration to the main function. In that sense, the ALAD encoded by whatever ALAD 
genotype may be able to work well in heme synthesis, except that the electric charge or 
molecular structure has some difference.  
2.7.3 Linkage Disequilibrium (LD) and Hardy-Weinberg Equilibrium (HWE) 
      Two important concepts have to be introduced in order to study SNP distribution 
in populations, Hardy-Weinberg Equilibrium and Linkage Disequilibrium.  
      Hardy-Weinberg Equilibrium (HWE) refers to the fact that gene and genotype 
frequencies in a randomly mating population are not going to change simply due to 
dominance and recessiveness of the allele. The HWE law emphasizes the constancy of 
gene and genotype frequencies through generations. This principle assumes random 
mating, and the population without migration, preferential selection, and any significant 
change in allelic frequencies due to mutation. If the distributions of alleles and genotypes 
don’t follow HWE in the population selected for a study. That means the sample is biased 
by other factors, and the allele frequencies calculated from this population are not 
representative.  
      Linkage disequilibrium (LD) is also a notion of population genetics. It refers to 
the situation that alleles at different loci are sometimes found together more or less often 
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than expected based on their frequencies. This non-random pattern contradicts the classic 
Mendel law of independent assortment. In LD, if the alleles from different loci tend to be 
inherited together, that means the occurrence of one allele virtually represents the 
frequency of the other. For this situation, they are supposed to be in the same linkage 
block, which may be retained and inherited from their ancestors without being disturbed.   
2.8    ALAD POLYMORPHISM AND ITS EFFECT 
      The effect of ALAD polymorphism on lead has been noticed and studied for 
decades. The traditional ALAD polymorphism, referring to the Msp SNP in exon 4 in this 
thesis, was first discovered by Battistuzzi et al (1981). The polymorphism has been the 
hot topic in lead research ever since. In literatures, ALAD polymorphism refers to this 
traditional polymorphism. The one other than Msp SNP in exon 4 will be specified as the 
combination of restriction enzyme name and the location where the mutation happens, 
such as HpyCH4 SNP in intron 6, which is a RFLP determined by HpyCH4 restriction 
enzyme happening in intron 6 of ALAD.  
      The Msp SNP yells two alleles, designated ALAD-1 and ALAD-2, which exhibit a 
codominant pattern of inheritance (Battistuzzi et al., 1981). A G→C transversion at 
position 177 of exon 4 transforms the wild type allele, ALAD-1, into variant allele, 
ALAD-2, resulting in the substitution of asparagine for lysine at amino acid 59 for 
ALAD-2 phenotype (Wetmur et al., 1991a). These two alleles determine three isozymes, 
designated 1-1, 1-2, and 2-2, which display similar activities but have different charges 
(Suzen et al., 2003; Battistuzzi et al., 1981).  
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2.8.1   ALAD Polymorphism Distributions in Various Populations  
      The frequencies of ALAD genotype differ by race. Generally, a bigger proportion 
of Caucasians express ALAD-2 allele in comparison with Asians. There is hardly 
ALAD-2 allele captivated in an African population. A direct evidence from Brazil showed 
a decrease in the frequency of ALAD-2 allele from 0.08 in Whites to 0 in Blacks in a 
subjective five point visual scale (White, Light Mulatto, Medium Mulatto, Dark Mulatto 
and Black) for Black ancestries (Sousa et al., 1991). Table 2.1  listed genotype 
frequencies from around the world (Kelada et al., 2001). All of these frequencies are in 
Hardy-Weinberg equilibrium.   
 
TABLE 2.1: Distributions of δ-aminolevulinic acid dehydratase (ALAD) genotype in 
previous studies 
ALAD Genotype Country 1-1 1-2 2-2 N Population Reference 
Canada  0.817 0.175 0.008 382 Workers Fleming et al., 1998 
Canada1  0.851 0.149 0 134 Workers Alexander et al., 1998
Greece  0.919 0.071 0.01 508 General Kapotis et al., 1998 
Japan  0.836 0.155 0.009 317 Workers & controls Sakai et al., 2000 
Poland  0.887 0.11 0.003 300 General Raczek et al., 1994 
Portμgal  0.827 0.165 0.008 1,043 General Amorim et al., 1994 
Taiwan  0.955 0.044 0.002 660 General Hsieh et al., 2000 
USA1  0.86 0.137 0.003 691 Carpenters Smith et al., 1995 
USA2  0.889 0.1 0.011 1278 Children Wetmur et al., 1991 
Turkey  0.787 0.2 0.013 230 General Suzen et al., 2004 
China1  0.827 0.165 0.008 215 General Lu et al., 2002 
China2  0.965 0.035 0 144 General Lu et al., 2002 
China3  0.936 0.062 0.002 530 General Zheng et al., 2001 
Canada1: British Columbia, USA1: (New Jersey) USA2: (New York) China1: (Uighur 
ethnic) China2: (Yi ethnic) China3: (Han ethnic) 
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2.8.2   Effect of ALAD Polymorphism on Lead Toxicokinetics  
      The effect of ALAD polymorphism on lead toxicokinetics was first manifested in 
its association with blood lead. Astrin et al. (1987) reported that PbB equal to or greater 
than 30 μg/dl occurred more frequently than expected for individuals heterozygous or 
homozygous for ALAD-2 allele (Astrin et al., 1987), suggesting that variant allele was 
associated with higher blood lead levels. The stronger and more convincing evidence of 
the association came from another study dealing with two much bigger populations. This 
study recruited 202 lead workers in Germany representing occupational exposure and 
1278 children with elevated free protoporphyrin levels in New York representing 
environmental exposure. For both populations, the individuals with ALAD 1-2/2-2 
genotype had PbB levels statistically higher than those with ALAD 1-1 genotype (worker 
population: P≤0.004; children: population P≤0.0001). The group of ALAD 1-2/2-2 
genotype had median PbB values about 9 μg/dl in workers or 11 μg/dl in children greater 
than similarly exposed ALAD 1-1 individuals (Wetmur et al., 1991b). The polygon of 
cumulative frequency for both populations showed that for each value of PbB, the 
distributions for ALAD-2 carriers were stochastically larger than the distributions for 
ALAD-1 homozygotes. The subsequent experiment looking at the biochemistry of ALAD 
polymorphism offered supportive evidences. As introduced before that the ALAD 
polymorphism results in a replacement of lysine in ALAD1-1 phenotype, which is 
positively charged, by asparagine in ALAD-2 phenotype, which is a neutral aminophenol. 
Therefore, compared to the ALAD1-1 enzyme, ALAD-2 isozymes are more 
electronegative and their affinity for lead, a positive ion is thought to be higher (Wetmur 
et al., 1991a). On the basis of these findings, it was hypothesized that ALAD-2 
individuals with higher PbB may be more susceptible to lead poisoning. In light of the 
dose-effect principle, it seems natural to conclude that ALAD-2 is a susceptible allele 
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during lead exposure.   
      Blood lead is the most important exposure index in lead research and ALAD is the 
principal lead binding protein in erythrocytes. The association between them is an 
indication of gene-environment interaction with public health significance. Many studies 
ever since have been carried out to explore this potential interaction, except that other 
lead indices like bone lead and chelatable lead are adopted in the study. Various findings 
have been reported and documented; nevertheless, a unanimous conclusion has yet to be 
reached. The studies so far are liable to imply that the working mechanism of ALAD 
polymorphism is far more complicated.  
      In South Korea, a study with 308 currently exposed lead workers found that the 
ALAD-2 allele was associated with PbB greater than or equal to 40 μg/dl (crude odds 
ratio =2.6, 95% CI, 1.1-6.3) (Schwartz et al., 1995). Data from 798 participants with 
occupational exposure demonstrated that subjects with the ALAD-2 allele had a higher 
adjusted mean PbB than those with ALAD 1-1 (on average, 2.9 μg/dl, p=0.07) (Schwartz 
et al., 2000a). On another occasion, the means of PbB were 23.1 and 28.4 μg/dl for 114 
ALAD 1-1 and 20 ALAD 1-2 male lead workers respectively. The crude comparison of 
these two values achieved a borderline line significance (p=0.08) (Alexander et al., 1998). 
The last study on occupational lead exposure found no difference by ALAD genotype for 
ZPP, PbB and ALAU in a population of Korean lead workers consisting of 44 ALAD 1-1 
homozygotes and 21 ALAD 1-2 individuals matched for exposure duration (Sithisarankul 
et al., 1997). 
      The association of ALAD genotype and blood lead was less likely to occur in 
populations with environmental lead exposure. An American population of middle-age to 
elderly men with environmental exposure failed to find any difference in PbB. The mean 
(SD) of PbB for ALAD 1-1 subjects was 6.2 (4.1) μg/dl and that for ALAD 1-2/2-2 
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people was 5.7 (4.2) μg/dl (Hu et al., 2001). In another Taiwanese population, although 30 
ALAD-2 carriers had blood lead levels 20% higher than those of 630 ALAD1-1 
homozygotes (mean PbB: 7.83 vs 6.51 μg/dl), the difference lost its significance after 
adjustment (Hsieh et al., 2000). Researches on two minority groups in china, 214 Uighur 
subjects and 144 Yi individuals, found no correlation of the ALAD polymorphism and 
PbB for both ethnic groups. Judging by their mean PbB levels, 7.6 μg/dl for Uighur and 5 
μg/dl for Yi, these subjects were exposed to mild lead doses (Lu et al., 2002).  
      Studies on children were in favor of the association of higher PbB with ALAD-2. 
The mean of PbB was 10.3 μg/dl (range, 4.5-26.4 μg/dl) for a children population made 
up of 109 boys and 120 girls of 6-10 years. The respective mean of PbB for ALAD 1-1 
and ALAD-2 group was 9.7 and 11.7 μg/dl, suggesting a 2 μg/dl higher PbB for people 
with ALAD-2 (P<0.05). In the multiple regression model of PbB, ALAD-2 allele 
contributed to an extra 3.2 μg/dl with statistical significance (P<0.01) (Shen et al., 2001). 
Another children sample had 23 ALAD-2 carriers and 347 ALAD 1-1 homozygotes. 
Crude comparison indicated that ALAD-2 group had a mean PbB 20% higher than the 
value for ALAD1-1 group (P=0.04). Paralleling to the outcome of PbB, ZPP was also 
found higher in ALAD-2 subgroup (13.07 μmol/L vs 9.90 μmol/L, P=0.02) (Zheng et al., 
2001b). A trend for higher blood lead levels in ALAD-2 carriers has been observed in the 
study (n=93 children) conducted in Chile. In ALAD-2 carriers, geometric mean (GM) of 
PbB was 16.4 μg/dl while the same index in ALAD1-1 individuals was 12.1 μg/dl 
(Perez-Bravo et al., 2004).   
      At this point of the review, it seems that, occupational lead exposure can cause the 
ALAD allele related difference in blood lead with ALAD-2 being associated with higher 
PbB. Environmental lead exposure is not strong enough to achieve PbB by genotype with 
exception of children populations. Smith et al (1995) has proposed that the effect of the 
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variant ALAD protein on PbB can only happen in high levels of lead exposure. It is the 
result of the saturation of other lead-binding sites and could thus be evidenced only 
transiently after exposure to high levels of lead (Smith et al, 1995). This idea is 
reasonable in a biochemical point of view. According to the study by Bergdahl et al 
(1997), at similar PbB levels, ALAD-2 carriers did have more lead bound to the ALAD 
enzymes than ALAD 1-1 homozygotes yet the difference was only 3% (p=0.03) 
(Bergdahl et al., 1997) and was present only in lead workers. The difference was not 
replicated in unexposed workers of this study (median of PbB: ALAD 1-2/2-2, 0.18 
μmol/l; ALAD 1-1, 0.19 μmol/l). Anyway in erythrocytes, the lead bound to ALAD 
ranged from 35-81% with the remains bound to other binding proteins (Bergdahl et al., 
1998). When the exposure level was low, the discrepancy caused by the polymorphic 
ALAD enzymes could be compensated for by other proteins binding lead. So the level of 
exposure must be sufficiently high.  
      Another study explored the ALAD-PbB relationship in a dose-effect fashion. The 
authors divided the sample into 3 exposure groups by mean PbB, high group (n=26, 
PbB=28.4 μg/dl), low group (n=31, PbB=10.4 μg/dl) and control group (n=30, PbB=4.2 
μg/dl). There were no significant differences among the three groups for PbB based on 
ALAD 1-1 and ALAD 1-2 (Wu et al., 2004). It was postulated that PbB less than 30 μg/dl 
was less likely to bring about the difference in PbB by genotype.  
      In spite of abundant evidences in ALAD polymorphism and blood lead, an 
agreement was hardly reached. The diversifying findings could be ascribed to the effect of 
ALAD polymorphism on other biological compartments containing lead, such as bone, 
which is able to contribute 20-25% of PbB at most (Cake et al., 1996). After all, blood 
lead is an informative lead index given the lead stored in each biological compartment 
interacts with each other through the constant exchange of the metal. The former detected 
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association between PbB and ALAD genotype may also be the outcome of differential 
partition, excretion and accumulation of lead in bone or other soft tissues by ALAD 
genotype. In order to elucidate how ALAD polymorphism acts on lead toxicokinetics, it is 
as necessary as meaningful to study other lead-containing tissues.  
      Some data implied that the ALAD genotype might modify the long-term retention 
and deposition of lead without the existence of difference in PbB. The significant 
comparisons in PbB between ALAD genotypes were not observed in the studies 
summarized in this paragraph. One study, with 38 ALAD 1-1 and 19 ALAD 1-2 persons 
matched for the duration of employment, found that, subjects with ALAD 1-2 excreted, 
on average, 24 μg less lead than did subjects with ALAD1-1 (P=0.05) during the 
four-hour urine collection after chelation. This may indicate that subjects with ALAD1-2 
had lower lead stores than those with ALAD 1-1 in that the amount of lead excreted after 
chelation partly reflects the stores of bioavailable lead. ALAD genotype was also shown 
to modify the relation between ALA and chelatable lead (Schwartz et al., 1997). In one 
study conducted by Smith et al (1995), patella lead minus tibia lead concentrations for 
each individual averaged 3.35 µg/g in ALAD-1 homozygotes and 8.62 µg/g in ALAD-2 
carriers (P=0.06). Based on this finding, it was speculated that there was a decrease in the 
relative distribution of lead to long-term bone stores for ALAD-2 carriers. On another 
occasion, ALAD-2 allele was found associated with decreased lead levels in both patella 
and tibia. The mean difference for Pb-Patella was 6.7 μg/g with a p value of 0.015 and 
that for Pb-Tibial was 5.4 μg/g with a p value of 0.055 (Kamel et al., 2003).  
      In contrast to the study by Kamel et al (2003), another study on 652 lead workers 
did not obtain the ALAD related difference in Pb-Patella, although the sample population 
had a 7 fold high mean Pb-Patella (75.2 μg/dl) (Theppeang et al., 2004). Sometimes, the 
excretion of lead did not appear to correlate with ALAD status as shown in the study by 
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Suzen et al (2003) (Suzen et al., 2003). The mean PbB and PbU were nearly the same for 
ALAD1-1 homozygotes (PbB, 34.4 μg/dl; PbU, 80.6 mg/gCr) and ALAD1-2/2-2 
individuals (PbB, 34.9 μg/dl; PbU, 78.5 mg/gCr). 
      To evaluate the functions of ALAD polymorphism, a total of 798 lead workers, 79 
of them being ALAD 1-2, were recruited in South Korea. This project did see the higher 
PbB in the subjects with the ALAD-2 allele in adjusted analysis (p=0.01) whereas there 
was no difference in Pb-Tibia. For chelatable lead, the mean difference of 18.6 μg by 
genotype did not achieve statistical difference (Schwartz et al., 2000a). The regression 
models of PbB on Pb-Tibia found no evidence of effect modification of ALAD 
polymorphism on the relation of PbB to Pb-Tibial. However, ALAD polymorphism could 
modify the relation of CCr to Chelatable lead based on the fact that subjects with 
ALAD-2 allele had higher increase in Pb-Ch with increasing CCr than did subjects 
without the allele (Schwartz et al., 2000a).  
      Allowing for the complexity of lead metabolism, one comprehensive study 
addressing the detailed lead distribution among bone and blood was reported in a 
population with environmental lead exposure (Hu et al., 2001). The strength of this study 
was its investigation into the interactions occurring in the course of lead distribution. It 
was with a sample of 726 middle-aged and elderly men with 7 and 111 subjects 
homozygous and heterozygous for the ALAD-2 allele. The means (SD) of PbB, Pb-Tibia, 
Pb-Patella for ALAD 1-1 were 6.2 μg/dl, 22.1 μg/g and 31.9 μg/g, respectively and those 
for ALAD 1-2/2-2 were 5.7 (4.2) μg/dl, 21.2 (10.9) μg/g and 30.4 (17.2) μg/g respectively. 
The authors did not find significant differences by genotype with respect to lead levels in 
trabecular bone or blood. In contrast to what was reported by Smith et al (1995) (Smith et 
al., 1995), the patella-tibia lead difference for ALAD1-1 and ALAD 1-2/2-2 was almost 
the same with the former being 10 μg/g, the latter being 9.2 μg/g, suggesting that ALAD 
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status did not change the lead partition among bones. The only difference was found with 
lead levels in cortical bone, the wild type homozygotes had Pb-Tibia levels 2.55 μg/g 
higher than those with variant allele.  
      Regression models illustrated the interaction between Pb-patella and ALAD 
genotype in relation to PbB. ALAD1-2/2-2 individuals inclined to have a lower PbB when 
Pb-patella was below 40 μg/g, and a higher PbB when Pb-patella levels was above 60 
μg/g. This probably means that ALAD polymorphism modifies movement of lead from 
bone into blood, with ALAD 1-2/2-2 genotype individuals possibly being less prone to 
mobilizing bone lead when bone lead levels are low, and more prone to mobilizing bone 
lead when bone lead levels are high (Hu et al., 2001). 
      A retrospective study answered some difficult questions in the complicate 
relationships between ALAD polymorphism and lead toxicity with the assistance of 
follow-up information (Fleming et al., 1998). The project studied a population of 381 lead 
workers with 70 of them expressing ALAD-2 allele. The mean PbB of 303 ALAD 1-1 
participants was 22.85 μg/dl while that of the 65 ALAD1-2/2-2 subjects was 25.18 μg/dl 
(P = 0.04). The mean of serum lead concentration, representing the lead concentration in 
plasma, was 2.85 μg/l for the people with ALAD1-1 and 3.35 μg/l for the people with 
ALAD1-2/2-2. The difference was of borderline statistical significance (P<0.06). Thus 
the elevated mean serum lead levels affirmed the elevated mean blood lead levels for 
workers in the ALAD 1-2/2-2 subgroup. 
      The long-term distribution of lead seems to be independent of ALAD genotype in 
that none of the bone lead indices was found different by ALAD genotype. The means 
(SD) of Pb-Tibia and Pb-Calcaneus were 41.19(1.76) μg/g and 71.57(3.38) μg/g for the 
ALAD1-1, and 42.66 (3.37) μg/g and 72.32 (6.15) μg/g for ALAD1-2/2-2 subgroups. 
Lead partition within skeleton was not associated with ALAD genotype because neither 
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lead difference between these two bone sites nor the correlation of Pb-Tibial to Pb-Patella 
showed statistical difference by ALAD status (Fleming et al., 1998).  
      The most valuable information offered by this study was the secular trend of PbB 
and plasma Pb. Over the last 10 years, the mean PbB of ALAD1-2/2-2 subgroup was the 
higher of the two ALAD subgroups for each and every 6-month interval. The magnitude 
of the difference was about 1.6 μg/dl or 5.3% on average, and was fairly constant over 
time. Furthermore, the blood lead records dating back more than 20 years indicated an 
PbB elevation in ALAD-2 individuals (Fleming et al., 1998). This was such a strong 
evidence for the association of higher PbB with ALAD-2 allele that any converse 
association observed at occupational exposure status might need further clarification. 
      On the basis of secular serum lead concentration record, a cumulative distribution 
of serum lead levels subdivided by ALAD genotype was generated Figure 2.9).  
 
  
      Figure 2.9 clearly illustrated a bigger proportion of ALAD1-2/2-2 individuals than 
Figure 2.9: Serum lead concentration as a function of cumulative 
percentage of sample (Fleming et al., 1998)  
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ALAD1-1 homozygotes at any given value of PbP. The secular trend of PbP by genotype 
was consistent with the time trend of PbB although the difference in PbP between 
genotypes did not remain constant.  
      The genotype-related release of lead from bone was also explored in the 
population of either retired workers or the workers free from lead contact for a long time. 
Regression models of PbB did not show any modifying effect of ALAD genotype on the 
relations of PbB to Pb-Tibia or Pb-Calcaneus, suggesting that lead released from bone 
was the same for ALAD1-1 and ALAD1-2/2-2 group (Fleming et al, 1998).   
      For workers hired later than 1977, the regression models describing the 
relationship between Pb-Tibia linear or Pb-calcaneus and cumulative blood lead index 
indicated more efficient uptake of lead from blood into bone for ALAD1-1 homozygotes 
in comparison with ALAD-2 carriers. If other organs followed a pattern of kinetics 
similar to that demonstrated for bone, this characteristic uptake of lead to bone could 
signal a protective mechanism from the deleterious effects of lead for ALAD-2 
individuals because the ALAD-2 subunit would limit the overall transfer to the tissue 
(Fleming et al., 1998).  
      In summary, ALAD polymorphism can modify lead kinetics and its function is 
comprehensive and complicated. Firstly, ALAD-2 enzymes keep more lead in 
erythrocytes than ALAD1-1 enzymes, so that ALAD-2 allele is associated with higher 
PbB in populations with occupational lead exposure. Compared to ALAD-1, the variant 
allele seems to be able to decrease lead uptake into cortical bone and increase the 
mobilization of lead from trabecular bone. However, the body lead burden is not affected 
and the pattern of lead distribution in skeleton is similar across the ALAD genotypes. 
Finally, the amount of lead physiologically available to human organs is more for 
ALAD1-1 homozygotes than ALAD-2 carriers.  
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2.8.3   Effect of ALAD Polymorphism on Health Outcomes (Two Scenarios) 
      The ALAD polymorphism has proven effect on lead kinetics. The implication of 
this effect in relation to target organs is still unknown yet of public health concern. 
Currently, it is uncertain which allele is susceptible to lead and which one is lead-resistant. 
Two-scenario theory has been put forward as a basic theory for future exploration. 
Described in a review by Onalaja and Claudio, two-scenario says “in the first, increased 
binding of lead to ALAD, especially to ALAD-2 enzyme could result in increased 
distribution of lead to other target organs such as kidney and brain. Conversely, it is 
possible that ALAD could serve as a sink, keeping lead sequestered in the blood”. “in this 
case, people who have the ALAD-2 allele could experience less severe effects of lead on 
kidney and brain and lesser accumulation of lead in bone while at the same time having 
higher blood lead levels than ALAD-1 homozygotes exposed to the same doses of lead” 
(Onalaja and Claudio, 2000).   
      The epidemiologic approach trying to distinguish the susceptible allele is to 
encompass health outcome parameters in the study. By seeking the associations of ALAD 
genotype with health effect, the implication of the ALAD polymorphism is expected to be 
fully uncovered.  
2.8.3.1  ALAD-2 allele is resistant to lead exposure 
      ALAD-2 allele has been suggested a protective factor for lead intoxication in 
several studies. Among the workers with the highest lead exposure, Schwartz et al (1995) 
found that the ALAD-2 allele was associated with lower ZPP levels after controlling for 
PbB, even though ALAD-2 was significantly associated with PbB over 40 μg/dl. 
Therefore the authors proposed that ALAD-Lead complex bound and sequestered lead 
from being available to other vital organs so that ALAD-2 individuals with more lead 
sequestered in erythrocytes had better outcome reflected by relatively lower ZPP. The 
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small sample size (n=18) undermined the validity of the conclusion (Schwartz et al., 
1995). A consistent study showed that ZPP levels were higher in ALAD-1 workers and 
the difference by genotype was most pronounced at PbB over 40 µg/dl. On top of that, the 
slope of PbB in ZPP-PbB linear model was greater for ALAD1-1 genotypes in 
comparison with ALAD-2 carriers (2.83 vs 1.50, P=0.06) (Alexander et al., 1998), 
showing a modifying effect by the ALAD polymorphism on the association between PbB 
and ZPP. In this study, the mean PbB for ALAD1-1 subjects (23.1 μg/dl) was lower than 
its counterpart (28.4 μg/dl) for ALAD1-2 subjects (p = 0.08) (Alexander et al., 1998). A 
study about occupational lead exposure did not found any difference between 44 ALAD 
1-1 individuals and 21 exposure duration matched ALAD 1-2 in terms of PbB, age, ZPP 
and ALAU concentration. The plasma concentration of ALA remained significantly 
elevated (P = 0.032) in ALAD1-1 subjects after adjustment for PbB and age 
(Sithisarankul et al., 1997). However, the significance may be caused by the three 
extreme values in ALAD 1-1 group.  
      Another study found the evidence that ALAD wild type homozygotes are more 
susceptible to cytogenetic effects of lead exposure. Without the difference in PbB, ALAD 
1-1 workers had statistically higher percentage of high-frequency cells HFC (P<0.05) in 
comparison to ALAD 1-2/2-2 workers (Duydu and Suzen, 2003). Compared with those 
who have ALAD 1-2/2-2 genotypes (n=13), 106 lead workers with ALAD1-1 genotypes 
had significantly higher ALAU and poorer neurobehavioral scores although PbB was 
comparable between ALAD groups (Chia et al., 2004). In a sample of 72 male lead 
workers, with the nearly same PbB and urine lead concentration, ALAD-1 homozygotes 
showed significantly higher levels of ALAU (Suzen et al., 2003). ALAD 1-1 individuals 
might be an increased risk to the disturbance in neural functions in high lead exposure.  
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2.8.3.2  ALAD-2 allele is susceptible to lead exposure   
      ALAD-2 doesn’t always show its protection against lead. As a matter of fact, it 
appears to be vulnerable to lead attack regarding some organs like kidney. So far 
evidences have suggested an ever complicate fashion in which ALAD polymorphism 
affects human response to the metal. 
      With regard to renal functions, the elevated BUN and serum uric acid was 
observed in ALAD-2 individuals and this trend remained of borderline statistical 
significance in multiple logistic regression models (p=0.06 and p=0.07, respectively). 
However the only different exposure index between ALAD1-1 and ALAD1-2/2-2 groups 
was the value of Pb-Patella minus Pb-Tibia, averaged 3.35 µg/g in ALAD 1-1 and 8.62 
µg/g in ALAD-2 carriers (p=0.06) (Smith et al., 1995). Taken together, the authors 
proposed that the decreased distribution of lead to cortical bone for ALAD-2 carriers 
would be likely to increase the cumulative amount of lead accessible to the kidney, 
potentially exacerbating toxicity at this target organ. In another population of 89 lead 
workers, both exposure parameters (PbB, Pb-bone) and outcome parameters (Sβ2m, 
Uβ2m, TNAG and serum albumin) were similar for ALAD1-1 homozygotes and ALAD-2 
carriers. Nevertheless, concentrations of urinary creatinine and calcium were lower in 
ALAD-2 subjects than those in ALAD 1-1 subjects with statistical significance (P=0.008; 
p=0.003 respectively). There appeared a tendency of ALAD-2 to have higher SCr levels 
for this population. The results indicated the presence of ALAD allele-specific differences 
in kidney function, probably worse for ALAD-2 carriers (Bergdahl et al., 1997).  
      On a separate occasion with 709 subjects with general exposure to lead, the 
comparisons between ALAD 1-1 and ALAD 1-2/2-2 found no significant differences in 
serum uric acid, SCr or estimated CCr. A significant linear regression of serum uric acid 
on Pb-Patella (p = 0.040) was observed above a threshold Pb-Patella of 15 μg/g among 
 - 59 - 
the ALAD 1-2/2-2 genotype individuals. In contrast, among the wild-type homozygotes, 
the same linear relationship was only suggestive with a threshold Pb-Patella of 101 μg/g 
and a p value of 0.141 . Through multiple regression models, a positive and significant 
interaction of Pb-Tibia with ALAD genotype was detected in relation to SCr, showing 
ALAD-2 subjects had about 3-4 fold higher SCr than did individuals with ALAD 1-1 (Wu 
et al., 2003).  
      Weaver et al (2003) analyzed data from 798 lead workers. After adjustment, 
participants with the ALAD-2 allele had lower SCr and higher calculated CCr. The effect 
modification by ALAD on associations between PbB and DMSA-chelatable lead and/or 
three renal outcomes was also observed. Among those with the ALAD1-2 genotype, 
higher lead measures were associated with lower BUN and SCr as well as higher 
calculated CCr (Weaver et al., 2003b). This might suggest that lead induced 
hyperfiltration is easier to occur in ALAD-2 carriers.  
      These studies appear to support that ALAD-2 is a susceptible allele regarding the 
renal functions.  
2.8.4   Comprehensive Analysis of ALAD’s Effect  
      It seems quite clear that the classical ALAD polymorphism is able to influence the 
physiological process of lead. At the same time, it is difficult to come to a decision as to 
which allele is in fact the risky allele. Different measures of outcome have indicated that 
each genotype is more susceptible to one or more adverse effects in comparison with the 
other.  
      Based on the evidence of lead kinetics, ALAD-2 should be the susceptible allele, 
even though two-scenario theory projects an equivocal explanation. As indicated in the 
section of lead distribution, the effect of lead on a specific organ depends on the amount 
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of the metal available to that organ. That is, the allele usually associated with more lead 
bioavailable to organs will be the susceptible allele. Complying with the curvilinear 
relationship between PbB and PbP (Bergdahl et al, 1997), which is the very index for 
bioavailable lead, ALAD-2 individuals should have higher PbP determined by the higher 
PbB associated with ALAD-2 allele (Wetmur et al, 1991; Fleming et al, 1998). The more 
direct proof was that serum lead concentration was constantly higher for ALAD-2 carriers 
over 20 years of time (Fleming et al, 1998). So in comparison with ALAD1-1 
homozygotes, ALAD-2 carriers have more lead ready to exert on organs like kidney and 
brain. No wonder studies on kidneys reviewed here all suggested that ALAD-2 is the 
vulnerable allele with respect to classical renal functions. 
      Further evidence surrounding ALAD polymorphism in relation to the neurological 
dysfunction put some doubts on the former speculation. The results obtained in this area 
are more likely to suggest that ALAD-2 is a protective allele. The ALAD-2 individuals 
were related to low urinary concentration of ALA (Sithisarankul et al., 1997; Chia et al., 
2004) and had better performance in neurological test (Bellinger et al., 1994; Chia et al., 
2004). The underneath logic usually proposed was that more lead is sequestered in 
erythrocytes for ALAD-2 carriers so that there is less lead available for toxic exertion in 
subjects with this allele. The hypothesis is applicable to the bone as demonstrated in the 
study by Fleming et al (1998) (Fleming et al., 1998). Due to the incapability of measuring 
lead concentration in organs like kidney or brain, there is no such direct evidence of the 
competitive binding to lead between erythrocytes and other organs. The results in studies 
about ZPP may come up as supporting evidence. Two studies (Schwartz et al., 1995; Kim 
et al., 2004) observed that ALAD-2 subjects might have lower bioavailable lead reflected 
by the levels of ZPP, which was thought to represent the bioavailable lead as blood lead 
strongly bound to ALAD isozyme should not inhibit ferrochelatase (Schwartz et al., 
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1995).  
      Whether the lead available to vitals organ is really less in ALAD-2 carriers than in 
ALAD1-1 homozygotes is still unknown? The key to the question may lie in the animal 
studies, in which lead content in any tissue can be calibrated.  
2.9    PROBLEMS IN RESEARCH 
Does ALAD polymorphism affect health outcomes independent of lead exposure? 
      Most authors so far believe that the exertion of ALAD on health outcome is 
through its influence on the pharmaceutical dynamics of lead. However, whether the 
ALAD polymorphism can take effect independent of lead exposure is still unknown to us. 
In quite a few studies, parameters for organ’s function showed difference by genotype 
whereas the exposure indices were similar or being adjusted in the models (Sithisarankul 
et al., 1997; Schwartz et al., 2000a). Short of the significant relationship between PbB or 
Pb-bone and health parameters, significant difference in health parameters by genotype 
were reported in some studies (Wu et al., 2003).  All these results seem to suggest that 
ALAD can affect the health outcome irrespective of the presence of lead.  
Is ALAD the main binding protein of lead in other cells?  
      It is pretty certain that ALAD is the principal lead binding protein in RBCs. 
Whether it plays a same role in other cells are in doubt. However, the present data do not 
seem to support the idea. Although liver and kidneys have high ALAD activities relative 
to other organs, this may be due to the blood allocated to them. Experimental studies have 
found that acyl-CoA-binding protein (Smith et al., 1994) is an important lead binding 
protein in renal cells. No similar evidence was reported for ALAD.  
Statistical Method Employed  
      Crude and/or adjusted comparisons are the most popular statistics used to find out 
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the true difference between wild type and variant allele. This category of methods utilizes 
t-test or GLM adjusting confounders to compare means of exposure indices and/or health 
indices reflecting the dysfunction of organs. 
      Some authors pay attention to the effect modification by ALAD polymorphism. 
They first explore the basic linear relation of lead indices to health indices. On top of that, 
the cross product of ALAD genotype and lead indices is added in the regression model to 
detect the possible modification of the lead-health relation by ALAD genotype. 
Sometimes the results from two methods lead to contradicting conclusion as indicated by 
the study by Wu el (2003) (Wu et al., 2003). This is not surprising because they were 
regarding different aspects of one question.  
      The method searching for effect modification should be preferably considered for 
several reasons: 1) the primary goal of the research on ALAD polymorphism is to confirm 
the gene (ALAD gene) and environment (lead exposure) interaction that makes the 
population with certain allele more vulnerable to lead. The essential of the topic is to see 
if ALAD polymorphism can exacerbate/alleviate the lead’s exertion to make the metal 
more/less harmful to human. The statistical methods therefore should be directed to seek 
the effect modification by ALAD polymorphism. Simple comparisons between genotypes 
have less power to serve the purpose. 2) Getting back to the physiological reality, it is the 
lead instead of ALAD that is the cause of the disease. Quite a few studies using 
comparison method give us an impression that ALAD works on target organs independent 
of the existence of lead, because exposure indices have been adjusted or the significant 
exposure-disease relationship doesn’t exist (Duydu and Suzen, 2003; Sithisarankul et al., 
1997). 3) Most researchers believe that the positive findings are more likely to be 
captured when exposure level is high (Smith et al., 1995; Suzen et al., 2003; Alexander et 
al., 1998). A threshold of exposure level therefore is suggested indicating that ALAD 
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polymorphism may work in disparate ways below or above certain value of PbB. Under 
such circumstances, either type of allele can be considered susceptible in the comparison 
analysis depending on the exposure level to which the selected population is exposed. The 
effect modification analysis is exploring the discrepancy in the progression of organ’s 
disorder in response to the increasing dose of lead. This analysis can avoid the problem of 
“threshold” and work with mildly and heavily exposed populations. Plus, it is of more 
meaning to watch the effect of the metal on the deterioration of the health than the 
comparison of health outcome at a cross-sectional plane.  
Gene-Gene Interaction  
      Other genetic polymorphisms capable of affecting lead metabolism could also 
magnify or alleviate the function of ALAD polymorphism, so called gene-gene 
interaction. The prominent one is the polymorphic gene of vitamin D receptor involved in 
the regulation of calcium mineralization and resorption. BsmI RFLP is the most widely 
studied VDR polymorphism. The workers with the VDR B allele had significantly higher 
patella lead than lead workers with the VDR bb genotype (Theppeang et al., 2004). On 
average, the diastolic blood pressures for VDR B allele lead workers were 1.9-2.5 mm Hg 
higher than did lead workers with the VDR bb genotype (P=0.04)(Lee et al., 2001). The 
VDR genotype was also found to modify the relation between age and Pb-Tibia; subjects 
with VDR B allele had larger increase in tibial lead concentrations with increasing age 
(Schwartz et al., 2000b). One study even detected an association of VDR and ALAD 
polymorphism. The lead workers homozygous for the ALAD-1 allele were much less 
likely to have the VDR bb genotype (crude OR=0.29, 95%CI [0.06-0.91])(Schwartz et al., 
2000a). Other SNP in ALAD also can affect lead metabolism so as to offset the 
significance caused by conventional ALAD polymorphism just like gene-gene interaction. 
Kamel et al (2003) reported an Msp SNP at the location of intron 2 in ALAD that was 
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associated with decreased bone lead levels (Kamel et al., 2003).  
      For almost all the studies conducted so far, none of them guarantees the even 
distribution of VDR or other ALAD polymorphisms across genotype groups by ALAD 
SNP in exon 4. These unknown factors make a good cause for the diversifying results 
from past studies.  
Healthy-worker Effect 
      Healthy-worker effect must be taken into account during the analysis of ALAD 
studies on occupational exposed workers. It occurs if the participants with worse health or 
lead indices would be eliminated from the population. The first problem arising is the 
putative association of PbB with ALAD allele. Depending on the requirements of 
elimination, healthy-worker effect can associate higher PbB with either ALAD-1 or 
ALAD-2 allele. In the study by Bergdahl and coworkers, Swedish regulation would 
remove the workers with abnormal PbB from lead work. As a result, the ALAD-2 
individuals were removed due to their tendency to get higher PbB. At last, the higher PbB 
was related to ALAD 1-1 genotype (Bergdahl et al., 1997). On another occasion, 
healthy-worker effect related the higher PbB with ALAD1-2/2-2 genotype (Schwartz et 
al., 1995). In that study, the workers with worsen ZPP would be excluded so that 
ALAD1-1 homozygotes, who are liable to get higher ZPP levels at similar exposure status 
(Zheng et al., 2001b; Kim et al., 2004), were removed, leaving the ALAD-2 carriers with 
higher PbB in the population.  
      The second problem arising from health-worker effect is the biased distribution of 
ALAD genotypes. Over a certain period of time, the healthy allele may work as a 
selection factor to keep subjects with the weak or strong allele in the population 
depending on the conditions of subject elimination. For a particular population, the risky 
or healthy allele may concentrate at the time of sampling. Bergdahl et al (1997) showed 
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that ALAD-2 allele occurred less frequently among lead-exposed workers than in 
unexposed controls (Bergdahl et al., 1997). An effective tool to judge a biased ALAD 
distribution is Hardy-Weinberg Equilibrium (HWE). If the sample follows HWE, the 
frequencies of ALAD allele are still representative.  
      Healthy-worker effect generally is a mild to modest effect at relatively high 
exposure status. It is not surprising that some study did not catch the difference in the 
percentage of ALAD-2 in the 3 groups of lead workers classified by PbB (Wu et al., 
2004), because the exposure level is low. Theoretically, health-worker effect is unlikely to 
occur under community exposure because the subjects will not be removed from the 
population however worse their parameters become. One study found that ALAD-2 
carriers were more frequent within the area defined by a distance of 200 meters from lead 
source (27%) than in areas more than 200 meters (5%) away. The authors failed to clarify 
the reasons for the elimination of subjects, so the finding can only be interpreted as a 
coincidence (Perez-Bravo et al., 2004).   
Summary:  
      The literatures reviewed above very much demonstrated that the study on the 
ALAD polymorphism and lead toxicity is a multi-disciplinary and multi-facet scientific 
issue covering across population genetics, molecular genetics, occupational health as well 
as epidemiology. More research needs to be done before the solid conclusion can be made. 
Under this circumstances, trying to make contributions to this scientific issue, we 
conducted a cross-sectional study with the following objectives, 1) Figuring out the 
ALAD polymorphism distribution in a Vietnamese population. 2) Establishing an 
association between lead exposure and renal function reflected by urine concentration of 
low molecular weight protein and lysosome. 3) Identifying susceptible ALAD alleles by 
detecting the interaction between ALAD genotypes and blood lead 4) Recommending 
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sensitive and specific EBEs for renal function impairment induced by lead exposure. We 
attempted to find out some evidences for the hypotheses that, 1) Urine low molecular 
weight protein and lysosomes are better EBEs for early renal damage caused by lead than 
clinical renal function indices currently used, 2) ALAD SNPs other than Msp SNP in 
exon 4 (the classical ALAD polymorphism), are able to affect the lead toxicity with 
regard to renal damage. 3) The Vietnamese population has the similar ALAD 
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CHAPTER THREE 
MATERIAL AND METHOD 
3.1    EPIDEMIOLOGY SECTION 
3.1.1   Study Site  
      Hai Phong, which means "coastal defence", is a big city recognized as the second 
biggest seaport of Vietnam. It is also the industrial and commercial center in North 
Vietnam. The factory selected for study is a lead battery manufacturer which has 323 
active workers with most of them being males.  
      The factory manufactures lead accumulator batteries. Basically, the work process 
consisted of melting down lead ingot which was then cast into grid (antimonial lead). 
Lead oxide was produced in a separate process by which the lead ingot was melted down 
and chemical additives and acid were added to the melted lead. The lead oxide paste was 
attached onto grid antimonial lead and dried in an oven. The dried plates were then 
formed to lead peroxide (positive) and spongy lead (negative) through electrical charging. 
The formed coated plates were then cut, brushed and polished into the required shapes. 
This was then assembled into the battery casings and the rods joined together by melting 
lead ingot to hold the rods together. The work process is summarized in the Figure (3.1.1), 
the photographs showed in the thesis were taken from the site.  
      Lead is present in an inorganic form in the entire process of production. During 
the work, the only personal protective equipment is face mask which does not look so 
effective. The past record of lead concentration in soil, water and air exhibited that the 
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Fig 3.1.3:  Stacking of lead accumulator (2) 












Figure 3.1.5: Assembly of lead accumulator (2) 
 
 












Figure 3.1.7: Welding of lead accumulator (2) 
 












Figure 3.1.9: Final product--lead battery 
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3.1.2   Study Population  
      All workers from the production line as well as in the division of management and 
quality control were recruited into this study. The study population consisted of 323 
workers, of which 246 were occupationally exposed to lead, while the remaining 77 were 
not directly exposed to lead. Although these 77 workers were not directly exposed to lead, 
many had previous history of exposure. Some were still exposed, albeit less. As such, 
these workers were also considered subjects with occupational lead exposure. Most of 
them came from the low or middle class of the society. Basically, this was a Vietnamese 
population consisting of healthy active lead workers. 
3.1.3   Questionnaire  
      Information gathered included age, years of education, detailed occupational 
history, current and previous smoking habits. Alcohol intake was also documented 
carefully as it could confound the findings. Actual amount of alcohol consumption per 
day (i.e. types of drink consume and the estimate amount by number of bottles) and 
number of years of drinking were noted. The questionnaires employed are enclosed in 
appendix 1 and appendix 2.   
3.1.4   Sample Selection 
      After the study went through National University Hospital Institutional review 
board, field works were subsequently done by the research team from the department of 
Community Occupational & Family Medicine, National University of Singapore, led by 
associate professor Chia Sin Eng.  
      Signed consent was obtained for each worker before blood and urine samples 
were taken for subsequent analysis. The workers need to fill up a set of questionnaire first. 
Then spot urine and 10 ml of blood were collected from each worker during the medical 
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examination. Six workers giving a history of diabetes mellitus and/or hypertension were 
excluded. Twenty of the exposed lead workers were not present during the study period 
while 17 of them did not want to participate. Likewise, 10 out of 77 workers who were 
not directly exposed to lead were unwilling to give their urine and blood for analysis. As 
the study was strictly on a voluntary basis, the workers’ decisions in not giving urine and 
or blood were respected fully. Hence, 47 workers were excluded in the study giving a 
response rate of 85.4% (276/323).  
3.2    EXPERIMENT SECTION  
3.2.1   Measurement of Renal Parameters and Blood Lead  
      Blood and urine samples were stored at -300C until analysis. All the analysis had 
been done within 2 months upon arrival in Singapore. Blood samples were obtained by 
venepuncture with lead-free disposable syringes and were stored in heparinised lead-free 
polypropylene tubes. Blood lead concentration (PbB) was analyzed using atomic 
absorption spectrophotometry (Varian Spectra AA-30) with a graphite furnace. External 
quality control has been done yearly under the National External Quality Assurance 
Scheme (England) and Inter-laboratory Comparison Programme (Canada). Urine samples 
for analysis of ALAU (urinary amino levulinic acid), URBP (urinary retinol binding 
protein), Uα1m (urinary α1-microglobulin), Uβ2m (urinary β2 microglobulin), Ualb 
(urinary albumin), TNAG (total N-acetyl-beta-D-glucosaminidase in urine) are buffered 
(PH 7.2). All the urine parameters were adjusted for variability in urine flow using urinary 
creatinine and was expressed per gram of creatinine. Urine and serum creatinine 
concentrations were determined using standard laboratory techniques. Ualb, ALAU, 
URBP, Uα1m, Uβ2m, TNAG were measured by enzyme-linked immunosorbent assay 
(ELISA) using commercially available polyclonal antibodies or test kits. NAG was 
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determined using Noto’s method (Chia et al., 1995b). 
3.2.2   Genotype Identification 
Six polymorphisms located on the ALAD gene were selected for analyses in our study. 
They are MspI and RsaI, which span a 248bp region of the genomic ALAD sequence, Rsa 
in exon 5 (Ra939488, 232bp), HpyIV (234bp), HpyCH4 (213bp), and Sau3AI (282bp) 
polymorphisms. DNA extraction from whole blood samples were carried out using the 
conventional phenol-chloroform method. The products of interest were then determined 
through amplification by polymerase chain reaction (PCR), using primers designed with 
“ P r i m e r 3 ” .  T h e  f o l l o w i n g  p r i m e r s  w e r e  u s e d :  M s p / R s a :  F o r w a r d 
5’GCCATATGCAGCTTGGTTTC3’, Reverse 5’CTAAGAAGGGAGGTTGCGCT3’; 
Rsa in exon 5 (Rsa39488): Forward 5’TACCATATTCAGCTTGGTT3’, Reverse 
5 ’ G C C A A C T T C C C T T C T T A A G C 3 ’ ;  H p y I V :  F o r w a r d 
5’AGGCAATCCATCTGTTGAG3’, Reverse 5’AGGAGCCCTTCAGGACAGA3’; 
H p y C H 4 :  F o r w a r d  5 ’ A G G T G G C A G A G T G G C TA G G 3 ’ ,  R e v e r s e 
5 ’ C C C G G C A G T T C T G T G A T T C 3 ’  a n d  S a u 3 A :  F o r w a r d 
5’GAGGAGTCCCCCAGCTATT3’, Reverse 5’GAGCCCTTCAGGACAGAT3’. The 
amplification cycles were performed on the PTC-100, MJ Thermal Cycler, and optimized 
to ensure specific amplification of the products of interest. Each PCR reaction was 
performed in a final volume of 25 all, which included 10 ng of pure genomic DNA; 1.0 
μM of each primer; 200 μM each of dNTP; 1X Taq Buffer; 1.5 mM MgCl2 and 1.0 unit 
of Taq DNA polymerase (all from Promega), and topped up to the required volume with 
sterile distilled water. Restriction fragment length polymorphism (RFLP) method was 
applied to locate the sites of mutation. Restriction enzymes (all from New England 
Biolabs; NEB) were added to the PCR products according to commercial specifications. 
After enzyme digestion of PCR products were completed, the fragments were determined 
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on a 2.0% agarose gel (Seakem Agarose) and visualized on the Biorad Gel Doc 2000. 
3.3    STATISTICAL ANALYSIS  
3.3.1   Initial Screen of Data  
      Twenty eight people did not have any genotype measurements and had to be 
excluded from the analysis leaving a sample of 248 workers. The data set of these 248 
workers was used in all the subsequent analysis. For some of the biological samples we 
were not able to analyze all the parameters as some of the sample ran out before we could 
complete the test. 
      The distributions of variables were checked individually with histogram and one 
sample Kolmogorov-Smirnov (K-S) test for normality. Necessary transformation was 
undertaken to achieve normal distribution for all important variables. ALAU, Uα1m, 
Uβ2m, Ualb, URBP, Sα1m and Sβ2m had logarithm transformation. TNAG had square 
root transformation. The transformed variables all followed normal distribution with an 
insignificant p-value from one sample K-S test. The adequacy of transformation was 
justified by the residual plots in later regression analysis and by Levene’s tests in General 
Linear Model.  
      Scatter plots of each renal parameter (Y-axis, transformed value) and PbB (X-axis) 
were examined initially to identify linearity and extreme points. All Scatter plots 
suggested good linear relationships between PbB and each renal function. For each 
relationship, there were less than 2 outliers identified, including those identified by 
residual plots in the subsequent regression analysis. As such these outliers were excluded 
from the analysis. 
3.3.2   Statistical Method  
      Statistical analysis is aimed at solving two questions: 1) Is there any difference in 
 - 77 - 
means of blood lead or renal parameters between genotypes of each SNP after adjusting 
for known confounders 2) does the increase of PbB cause the same increase of renal 
parameters across genotype subgroups within each SNP studied?The first question was 
addressed with GLM by controlling over age, exposure duration, and body mass index 
(BMI), PbB and gender. The second question was addressed with multiple linear 
regression including an interaction term of PbB*SNP while adjusting for same 
confounders as adjusted in GLM. For both techniques, dependent variables were 
transformed values, Log_ALAU, Log_Ua1m, Log_Ub2m, Log_Ualb, Log_URBP, 
Log_Sα1m, Log_Sβ2m, square-root_TNAG. Independent variables are PbB, SNP, 
PbB*SNP and confounders, viz age, exposure duration, gender and BMI. The 
cross-product term of PbB and SNP (viz, Msp, HpyCH4, Rsa. etc) representing the 
interaction between PbB and SNPs can help to detect if there is a significant difference in 
β-coefficients of PbB in the regression model for subjects with wild type allele and the 
corresponding β-coefficients for subjects with variant allele (Applied Linear Regression 
Models, 4th edition, Kutner Nachtsheim). The beta of cross-product theoretically is the 
difference between two betas in regression models for each genotype group. All data is 
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CHAPTER FOUR 
RESULTS 
4.1    CHARACTERS OF THE POPULATION 
      The population had a mean age of 39.3 years with the oldest being 66 years old 
and the youngest being 20 years. The average exposure period was 15 years based on the 
data of 236 subjects. About 74% of the entire population was male. Self-reported 
information about personal habits like smoke and alcohol was collected with structured 
questionnaire. About 36% of them didn’t drink at all while 23.2% were regular drinkers. 
One hundred and four people were current smokers, accounting for 42% of the whole 
population. Non-smokers also took up slightly less than 42% of the sample. This 
information was summarized in the Table 4.1.  
Table 4.1: Characters of the population in study 
  N M (S.D.) (Min, Max) Range 
Age (ys) 248 39.3 (10.5) (20, 66)  46 
Years exposed (ys) 236 15 (10.2) (0.5, 41)  40.5 
BMI  244 20.18 (2.28) (15.43, 27.06) 11.63 
    
Gender    
Male 184 74.2%  
Female 64 25.8%  
  Total   248 
Smoke status    
Current smoker 104 42%  
Ex-smoker 40 16.1%  
Non-smoker 103 41.9%  
  Total    248 
Drink status    
No 89 36.2%  
Occasional 100 40.6%  
Regularly 57 23.2%  
  Total   246 
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      To determine if the population with SNP measurement was a biased sample, age, 
gender and exposure duration between subjects with or without SNP measurement were 
compared. There were no significant differences found with regard to these demographic 
variables (results were not presented here).  
     Being self-reported information, data about smoke and drink status were not 
reliable so that they were not compared and were not selected as confounders in the 
subsequent analysis. Table 4.2 presented the summary of the demographic characters by 
SNP.   
Table 4.2: Basic characters of the population by SNPs  
Gender  Age (ys) Exposure Duration (ys) SNP M  F  Mean SD N Mean (SD) (Min, Max) Range
1-1 168 58  39.5 10.6 214 15.4 (10.2)  (1, 41)      40Msp 1-2/2-2 13 5  36.4 9.8 18 10.8 (9.1)  (1, 27)      26
1-1 40 16  39.8 11 54 15.8 (11.2)  (1, 41)      40
1-2  86 28  38.4 10.3 107 14.3 (9.9)  (1, 39)      38Rsa 
2-2  55 17  39.7 10.7 69 15.0 (9.9)  (1, 36)      35
1-1 41 15  40 11 55 16.0 (11.3)  (1, 41)      40
1-2  81 32  39.3 10.2 105 14.9 (10.0)  (1, 39)      38Rsa39 
2-2  56 16  39 10.7 69 14.5 (9.5) (1, 36)      35
1-1 136 55  39.2 10.4 184 15.5 (10.2)  (1, 41)      40HpyCH4 1-2/2-2 20 5  40.9 10.7 23 13.9 (9.3) (1, 30)      29
1-1 131 42  39.8 10.4 163 15.3 (10.2)  (1, 41)      40HpyIV 1-2/2-2 44 20  38.1 10.9 62 14.4 (10.3) (1, 39)      38
1-1 106 31  38.3* 10.7 131 14.9 (10.1) (1, 39)      38Sau3A 1-2/2-2 53 29  41.4* 9.68 77 16.05 (10.0) (1, 41)      40
* p<0.05. T-test was applied in the comparisons of age and exposure duration. Chi-square test was 
applied to compare the gender composition.   
 
      The mean blood lead was 24.39 μg/dl and the highest value was 66.9 μg/dl. The 
lead exposure in this group of people could be considered modest. For renal indices 
(URBP, Uα1m, Uβ2m) with normal reference intervals, only the mean of URBP was 
slightly higher than the normal upper limit of 0.11 mg/gCr. The distributions of blood lead 
and renal parameters were summarized in the table below (Table 4.3). 
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Table 4.3: Distributions of blood lead and renal parameters 
 N Mean S. D. (Min,Max)   Range 
PbB (μg/dl) 247 24.39 13.62 (2.00, 66.90)   64.9 
Uα1m (mg/gCr) 244 6.82 1.91 (1.29, 27.32)   26.03 
Uβ2m (μg/gCr) 237 0.19 2.30 (0.02, 1.81)    1.79 
URBP (mg/gCr) 239 0.16 1.95 (0.03, 0.86)    0.83 
Ualb (mg/gCr) 239 7.06 1.73 (1.23, 34.12)   32.89 
TNAG (U/gCr) 236 2.82 0.18 (0.10, 7.60)    7.50 
ALAU (mg/gCr) 236 0.95 1.55 (0.34, 3.63)    3.3 
Sα1m (mg/l) 241 41.8 1.29 (20.84, 74.25)  53.42 
Sβ2m (mg/l) 244 1.45 1.31 (0.77, 2.85)    2.09 
 PbB, arithmetic mean; TNAG, square root mean; Uα1m, Uβ2m, URBP, Ualb, ALAU, Sα1m and 
Sβ2m geometric mean.  
4.2    ALAD SNPS & THEIR DISTRIBUTIONS 
      There were 46 ALAD SNPs listed at National Center for Biotechnology 
Information (NCBI) website (http://www.ncbi.nlm.nih.gov/SNP) as of June 2004 when 
we started measuring ALAD genotype. To explore the effect of these 46 SNPs on the lead 
toxicity, 6 of them were selected, Msp SNP and Rsa SNP in exon 4, Rsa SNP in exon 5 
(Rsa39), HpyIV SNP and HpyCH4 SNP in intron 6, and Sau3A SNP in intron 12. These 6 
SNPs were not in linkage disequilibrium confirmed by the Helix Tree software for 
linkage analysis (http://www.goldenhelix.com/pharmhelixtreefeatures.html).  
      The ALAD polymorphism, Msp SNP in exon 4 was very familiar as it was the 
commonly studied SNP. The Rsa SNPs in exon 4 and 5, which involves a T to C 
transition, were firstly reported in 1999 and 2000 respectively. To distinguish them from 
each other, the one occurred in exon 5 was referred to as Rsa39. Rsa SNP was a 
synonymous mutation, i.e. the change from wild type allele to variant allele did not alter 
the amino acid produced (tyrosine). In intron 6, a G to C transversion brought about the 
HpyCH4 RFLP. The second SNP in intron 6 was an HpyIV RFLP, a C in wild type gene 
was replaced by T in variant type. Sau3A RFLP involved a C to T transition in intron 12. 
HpyCH4, HpyIV and Sau3A SNPs were intronic polymorphisms. The gene products 
encoded by whatever genotype were supposed to be the same in terms of amino acid 
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sequence. The information above was presented in Table 4.4.  
Table 4.4: Characters of 6 ALAD SNPs in study  
SNP    Location W/V Year of Discovery Reference  
Msp        Exon 4  G/C 1981 (Battistuzzi et al., 1981) 
HpyCH4     Intron 6 G/C 2000 (Olson, 2000) 
HpyIV      Intron 6  C/T 2003 (Nickerson, 2003) 
Rsa         Exon 4  T/C 1999 (Nomiyama et al., 1999) 
Rsa39    Exon 5 T/C 2000 (Lee, 2000) 
Sau3A       Intron 12  C/T 2000 (Olson, 2000) 
W/V: wild type/ variant 
      Because of the inadequacy of sample, not every subject had all SNPs 
measurement. The coverage of SNP measurements was slightly below 80% for HpyCH4 
and Sau3A SNP. For the Msp, Rsa, Rsa39 and Sau3A SNPs, the coverage rates were at 
least 86%. The lack of SNP measurement was totally random and was not related to the 
status of SNP. The distributions of genotypes all followed Hardy-Weinberg Equilibrium 
(HWE) with a P value smaller than 0.05 based on the test of conformance to HWE. In 
general, the frequencies of the alleles and genotypes in our project were still 
representative. Table 4.5 illustrated the frequencies of genotypes and alleles of each 
ALAD SNP.  
Table 4.5: Distributions of ALAD SNPs  
SNP N ALAD-1 ALAD-2 1-1 1-2 2-2 
Msp 244 95.9% 4.1% 92.6% 6.6% 0.8% 
Rsa 242 46.7% 53.3% 23.1% 47.1% 29.8% 
Rsa39 241 46.7% 53.3% 23.2% 46.9% 29.9% 
HpyCH4 216 94.2% 5.8% 88.4% 11.6% 0 
HpyIV 237 85.2% 14.8% 73% 24.5% 2.5% 
Sau3A 219 76.9% 23.1% 62.6% 28.8% 8.7% 
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4.3    BASIC RELATIONSHIPS BETWEEN BLOOD LEAD AND RENAL 
INDICES (STEPWISE REGRESSION MODEL) 
      Scatter plots between renal parameters and blood lead suggested that there were 
linear relations between each renal parameter and PbB. Subsequent stepwise regression 
models revealed that blood lead was a significant predictor for Uα1m, Uβ2m, URBP, 
TNAG and ALAU. The independent variables initially entering the regression models 
were age, gender, exposure duration, BMI and PbB.  
The Relationship between Urinary α1 Microglobulin (Uα1m) and Blood Lead (PbB) 
 
      Scatter Plot of Uα1m_Log VS PbB and the least square line   
























      The linear regression between Ua1m_Log and PbB indicated in Figure 4.1 was 
subjected to stepwise regression analysis. The following table (Table 4.6) was the output 
of stepwise regression model.  
Figure 4.1: Linear relationship between Uα1m_Log and PbB  
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Table 4.6: Stepwise regression model of Ua1m_Log  
  B S. E. S.B. t Sig. 
DV: Ua1m_Log      (R2=0.186)   
Age (ys) 0.010  0.002  0.377  5.851  0.000  
Sex -0.163  0.041  -0.254  -3.975  0.000  
BMI (kg/m2) -0.019  0.008  -0.151  -2.389  0.018  
PbB (μg/dl) 0.003  0.001  0.128  2.036  0.043  
DV: dependent variable B: β coefficient; S.E.: standard error of β coefficient; S.B.: standardized β 
coefficient; Sig.: significance. Sex: male group is the reference group.  
      As displayed in the Table 5.6, PbB was a significant predictor for Uα1m along 
with age, sex and BMI. The Uα1m level increased with the increase of PbB concentration. 
One μg/dl PbB contributed to 1.007 mg/gCr Uα1m. 
The relationship between Urinary β2 microglobulin (Uβ2m) and blood lead (PbB) 
Scatter plot of Uβ2m_Log VS PbB and the least square line fitting the data. 



















       
       
      The linear regression between Uβ2m_Log and PbB was futher explored by 
stepwise regression models which was described in Table 4.6. 
Figure 4.2: Linear relationship between Uβ2m_Log and PbB  
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Table 4.7: Stepwise regression model of Uβ2m_Log  
  B S. E. S.B. t Sig. 
DV: Uβ2m_Log     R2=0.018   
PbB (μg/dl) 0.004 0.002 0.135 2.034 0.043 
DV: dependent variable; B: β coefficient; S.E.: standard error of β coefficient; S.B.: standardized 
β coefficient; Sig.: significance 
      PbB was the only significant predictor for Uβ2m yet accounted for just 1.8% of 
the variance of Uβ2m. One μg/dl PbB predicted 1.009 μg/gCr Uβ2m.  
The relationship between Urinary Retinol Binding Protein (URBP) and blood lead (PbB) 




        Figure 4.3 suggested that there was linear relationship between URBP and PbB. 
Stepwise regression model was used to confirm this hypothesis (Table 4.8). 
         
 
         
Figure 4.3: Linear relationship between URBP_Log and PbB  
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 Table 4.8: Stepwise regression model of URBP_Log  
  B S. E. S.B. t Sig. 
DV:URBP_Log      (R2=0.322)   
Sex -0.163 0.045 -0.246 -3.629 <0.001 
Age (ys) 0.005 0.002 0.185 2.823 0.005 
PbB (μg/dl) 0.003 0.001 0.136 2.044 0.042 
DV: dependent variable B: β coefficient; S.E.: standard error of β coefficient; S.B.: standardized β 
coefficient; Sig.: significance. Sex: male group is the reference group.  
      PbB was positively correlated with URBP with a statistical significance (B=0.003, 
P=0.042). The regression model was consistent to the upward trend of URBP in response 
to PbB increase (Figure 4.3).  
The relationship between Total N-acetyl-beta-D-glucosaminidase (TNAG) in urine and 
blood lead (PbB) 




      Figure 4.4 suggested a linear relationship between TNAG_SQRT and PbB. 
Stepwise regression model was further applied to explore the relationship (Table 4.9). 
Figure 4.4: Linear relationship between TNAG SQRT and PbB 
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Table 4.9: Stepwise regression model of TNAG_SQRT  
  B S. E. S.B. t Sig. 
DV: TNAG_SQRT       R2=0.227    
PbB (μg/dl) 0.006  0.002  0.188  2.893  0.004  
Years Exposed (ys) 0.006  0.003  0.133  2.039  0.043  
DV: dependent variable B: β coefficient; S.E.: standard error of β coefficient; S.B.: standardized β 
coefficient; Sig.: significance.  
 
      The two significant predictors for TNAG were blood lead and exposure duration, 
the variables measuring exposure level. They together explained 22.7% of the variance of 
TNAG. Therefore TNAG seemed to be a specific as well as sensitive renal index for lead 
exposure. The exclusion of age and sex during stepwise regression analysis was 
consistent with the previous finding about NAG reporting that its concentration in urine is 
not affected by age and sex (Price, 1992).  
The relationship between Urinary Aminolevulinic Acid (ALAU) and blood lead (PbB) 
      Scatter plot of ALAU_LoG VS PbB and the least square line  
 
      There was a linear relationship between ALAU_Log and PbB (Figure 4.5). The 
value of ALAU increased with the rise of PbB. Stepwise regression model was used to 
quantify the relationship (Table 4.10).  
Figure 4.5: Linear relationship between ALAU_Log and PbB  
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Table 4.10: Stepwise regression model of ALAU_Log  
  B S. E. S.B. t Sig. 
DV: ALAU_Log   R2=0.624   
PbB (μg/dl) 0.009  0.001  0.619  11.216  <0.001 
Sex 0.080  0.024  0.186  3.310  0.001 
BMI (kg/m2) -0.014  0.005  -0.168  -3.022  0.003 
Age (ys) 0.003  0.001  0.161  2.848  0.005 
DV: dependent variable B: β coefficient; S.E.: standard error of β coefficient; S.B.: standardized β 
coefficient; Sig.: significance. Sex: male group is the reference group.  
 
      ALAU seemed to be the most sensitive parameter to lead exposure with 62.4 % 
variance of ALAU being accounted for by the model.  
The relationship between urinary albumin (Ualb) and blood lead (PbB) 
Scatter plot Ualb_Log VS PbB and the least square line 
       
 
                  
 
      There was no linear relationship between PbB and Ualb_Log indicated by scatter 
plot (Figure 4.6) or regression model (results were not shown).   
 
Figure 4.6: Relationship between Ualb_Log and PbB 
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The relationship between Serum α1 microglobulin (Sα1m) and blood lead (PbB) 
      Scatter plot of Sα1m_Log VS PbB and the least square line  
 
 
      There was no linear relationship between Sα1m_Log and PbB indicated in scatter 







Figure 4.7: Relationship between Sα1m_Log and PbB 
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The relationship between Serum β2 microglobulin (Sβ2m) and blood lead (PbB) 





      There was no linear relationship between Sβ2m_Log and PbB indicated by scatter 
plot (Figure 4.8) or regression model (results were not shown).   
      In summary, ALAU and TNAG are two most sensitive indices to lead exposure 
because PbB was the most effective predictor for in their models. The regression models 
each explained a large percentage of the variation of these two outcome variables, 62.4% 
and 22.7% for ALAU and TNAG respectively. PbB was also the significant predictor for 
Uα1m, Uβ2m and URBP with varying effect in each model. In this population, the 
behavior of Sα1m, Sβ2m and Ualb were not relevant to lead or exposure duration, the 
variables measuring lead exposure. They were not treated as outcome variables for 
successive analysis.   
Figure 4.8: Relationship between Sβ2m_Log and PbB  
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4.4    MAIN EFFECT OF ALAD POLYMORPHISM ON BLOOD LEAD          
    AND RENAL PARAMETERS (GENERAL LINEAR MODEL) 
      The main effect of each SNP genotype was explored using General Linear Model 
(GLM) to adjust for confounders, which were age, sex, BMI, exposure duration, PbB and 
the cross-product of PbB and SNP. As there were no linear relationships between PbB and 
Ualb, Sα1m as well as Sβ2m, their results were not shown.  
      Tables 4.11 to 4.16 were the results of crude and adjusted comparisons for each 
ALAD SNP.  The means of renal parameters and blood lead were compared between 
subjects homozygous for wild type and subjects carrying variant allele. The crude 
comparison, conducted through student t-test or ANOVA, did not adjust for confounders 
whereas adjusted comparison, conducted through GLM, adjusted for the confounders 
listed ahead.  
Table 4.11: Comparisons of blood lead and renal parameters between Msp genotypes 
  Crude     Comparison  Adjusted    Comparison  
 1-1 1-2/2-2 P 1-1 1-2/2-2 P 
 N Mean N Mean  N Mean N Mean  
Uα1m (mg/gCr) 222 6.89 18 6.54 0.743 208 6.10 18 6.47 0.309
Uβ2m (μg/gCr) 216 0.19 17 0.22 0.474 203 0.18 17 0.24 0.289
URBP (mg/gCr) 217 0.17 17 0.14 0.323 205 0.15 17 0.14 0.911
TNAG (U/gCr) 215 2.84 17 2.55 0.417 204 2.77 17 2.81 0.746
ALAU(mg/gCr) 215 0.97 18 0.79 0.058 202 1.01 18 0.97 0.426
PbB  (μg/dl) 226 24.65 18 18.89 0.084 212 23.70 18 20.69 0.341
 
Table 4.12: Comparisons of blood lead and renal parameters between HpyCH4 
genotypes  
  Crude    Comparison   Adjusted    Comparison   
  1-1  1-2 P   1-1  1-2 P  
 N Mean N Mean  N Mean N Mean  
Uα1m (mg/gCr) 187 6.89  25 6.63 0.779 178 6.22 22 5.26  0.658 
Uβ2m (μg/gCr) 185 0.19  22 0.22 0.356 176 0.18 20 0.20  0.188 
URBP (mg/gCr) 185 0.16  22 0.17 0.827 177 0.15 20 0.13  0.300 
TNAG (U/gCr) 183 2.90  23 2.46 0.154 177 2.81 20 2.46  0.683 
ALAU (mg/gCr) 184 0.96  24 0.91 0.512 175 1.00 21 1.02  0.100 
PbB   (μg/dl) 190 24.64  25 22.59 0.465 182 23.95 22 22.46  0.589 
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Table 4.13: Comparisons of blood lead and renal parameters between HpyIV genotypes  
  Crude    Comparison   Adjusted    Comparison   
  1-1  1-2/2-2 P   1-1  1-2/2-2 P  
 N Mean N Mean  N Mean N Mean  
Uα1m (mg/gCr) 172 7.00  61 6.34 0.308 160 6.15 57 6.01  0.538
Uβ2m (μg/gCr) 166 0.18  60 0.19 0.708 155 0.18 56 0.19  0.645
URBP (mg/gCr) 167 0.17  60 0.15 0.416 156 0.15 57 0.15  0.961
TNAG (U/gCr) 163 2.84  62 2.78 0.776 154 2.78 58 2.78  0.761
ALAU (mg/gCr) 165 0.93  61 1.02 0.144 155 0.95 57 1.17  0.814
PbB   (μg/dl) 172 25.16  64 21.96 0.103 161 24.20 60 22.44  0.348
 
Table 4.14: Comparisons of blood lead and renal parameters between Sau3A genotypes  
  Crude    Comparison   Adjusted   Comparison   
  1-1  1-2/2-2 P   1-1  1-2/2-2 P  
 N Mean N Mean  N Mean N Mean  
Uα1m (mg/gCr) 134 6.56  81 7.11 0.386 126 5.87 76  6.31  0.347 
Uβ2m (μg/gCr) 130 0.18  79 0.19 0.635 122 0.18 75  0.18  0.980 
URBP (mg/gCr) 131 0.16  79 0.16 0.732 124 0.15 75  0.14  0.549 
TNAG (U/gCr) 130 2.99  80 2.51 0.016 124 2.92 76  2.52  0.532 
ALAU (mg/gCr) 130 0.90  80 1.01 0.066 123 0.93 75  1.08  0.180 
PbB  (μg/dl) 136 25.44 82 21.03 0.016 129 24.37 77  21.79  0.148 
 
PbB, mean; TNAG, square-root mean; Uα1m, Uβ2m, URBP and ALAU, geometric mean. Crude 
comparisons were done by t-test. Adjusted comparions were done by GLM. PbB model adjusted 
for age, sex, BMI, exposure duration. TNAG, Uα1m, Uβ2m, URBP and ALAU models adjusted 
for age, sex, BMI, exposure duration, PbB and the cross product of PbB & Sau3A.  
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  Table 4.15: Comparisons of blood lead and renal parameters between Rsa genotypes  
  Crude      Comparison   Adjusted       Comparison   
  1-1  1-2  2-2 P   1-1  1-2  2-2 P  
 N Mean N Mean N Mean  N Mean N Mean N Mean  
Uα1m (mg/gCr) 56 7.16 111 6.34 71 7.46 0.223 54 6.46 102 5.70 68 6.64 0.135 
Uβ2m (μg/gCr) 54 0.18 107 0.19 70 0.20 0.846 52 0.18 99 0.19 67 0.19 0.872 
URBP (mg/gCr) 55 0.18 107 0.16 70 0.17 0.705 53 0.16 100 0.14 67 0.14 0.263 
TNAG (U/gCr) 55 3.11 108 2.76 67 2.74 0.271 54 3.12 100 2.74 65 2.71 0.393 
ALAU (mg/gCr) 55 1.00 109 0.92 67 0.96 0.473 53 1.07 101 0.98 64 1.00 0.612 
PbB  (μg/dl) 56 23.04 114 23.87 72 25.92 0.444 54 22.05 105 23.36 69 25.34 0.333 
  
 
  Table 4.16: Comparisons of blood lead and renal parameters between Rsa39 genotypes  
  Crude    Comparison   Adjusted     Comparison   
  1-1  1-2  2-2 P  1-1  1-2  2-2 P 
 N Mean N Mean N Mean  N Mean N Mean N Mean  
Uα1m (mg/gCr) 56 7.42 110 6.17 71 7.37 0.096 54 6.48 100 5.78 68 6.60 0.095 
Uβ2m (μg/gCr) 53 0.19 107 0.17 70 0.21 0.279 51 0.18 98 0.17 67 0.20 0.283 
URBP (mg/gCr) 56 0.18 106 0.15 70 0.17 0.290 54 0.16 98 0.14 67 0.14 0.435 
TNAG (U/gCr) 55 3.13 108 2.80 66 2.65 0.180 54 3.08 99 2.83 64 2.57 0.933 
ALAU (mg/gCr) 55 1.00 109 0.93 66 0.95 0.580 53 1.03 100 1.02 63 0.97 0.738 
PbB  (μg/dl) 55 24.41 113 22.09 72 27.64 0.025 54 22.80 103 21.72 69 26.72 0.032 
PbB, mean; TNAG, square-root mean; Uα1m, Uβ2m, URBP and ALAU, geometric mean. Crude comparisons were done ANOVA. Adjusted comparions were 
done by GLM. PbB model adjusted for age, sex, BMI, exposure duration. TNAG, Uα1m, Uβ2m, URBP and ALAU models adjusted for age, sex, BMI, 
exposure duration, PbB and the cross product of PbB & Rsa39.  
 - 93 - 
      In the results of crude comparison, mean TNAG and PbB were significantly higher 
in Sau3A-1 homozygotes comparing to Sau3A-2 carriers, and conversely the mean ALAU 
was lower in Sau3A-1 homozygotes with borderline significance (Table 4.14). But all the 
significant results turned insignificant in their respective adjusted comparisons (p>0.1). 
The mean blood lead level of Rsa39 2-2 genotype (26.7 μg/dl) was significantly higher 
than that of Rsa39 1-1 (22.8 μg/dl) and Rsa39 1-2 (21.7 μg/dl) groups before and after 
adjustment. The mean effect of Rsa39 on Uα1m was only suggestive with a p value of 
0.095 (Table 4.16). The comparisons for Msp, HpyCH4, Rsa and HpyIV SNPs did not 
show any significant findings (Table, 4.11, 4.12, 4.13 and 4.15).  
4.5    EFFECT MODIFICATION OF ALAD POLYMORPHISM 
(MULTIPLE LINEAR REGRESSION) 
      The modifying effect of ALAD polymorphisms on lead toxicity in relation to renal 
function was explored by multiple linear regression (MLR) models. The cross-product of 
PbB and each SNP was added in each model to illustrate the modification effect of ALAD 
polymorphism on the association of PbB with each renal index.  
      Among 6 SNPs studied, HpyCH4 in intron 6 was shown to significantly affect the 
toxic effect of lead with regard to Uα1m, Uβ2m, and URBP. Rsa SNP in exon 4, Rsa in 
exon 5 (Rsa39), HpyIV in intron 6, Sau3A in intron 12 and Msp in exon 4 did not exhibit 
some effect on lead toxicity. Due to the limitation of space, the negative findings were not 
presented. The scatter plots of renal parameters an blood lead were generated to illustrate 
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4.5.1   HpyCH4 SNP in Intron 6 
4.5.1.1  Urinary α1-microglobulin (Uα1m) 
      The comparison of PbB-Uα1m_Log linear relationship between HpyCH4 
genotypes was illustrated in Figure 4.9. 

























<Y, original Uα1m_log; X, blood lead. ○: Blue loop represents points specified by value pair of PbB and 
Uα1m_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of PbB 
and Uα1m _Log for HpyCH4 1-2 heterozygotes> 
         The figure above (Figure 4.9) showed that the regression line for HpyCH4 1-2 
group was different from the line for HpyCH4 1-1 group with the former line having a 
negative slope. The negative correlation between PbB and Uα1m for HpyCH4 1-2 
individuals was not biologically plausible because fundamentally, lead can only increase 
the concentration of Uα1m. The negative linear relation observed was the confounding 
effects of age, exposure duration etc. Still, the regression for variant group implied that 
HpyCH4 1-2 genotype was more resistant to lead than HpyCH4 1-1 genotype.  
Figure 4.9: Regression lines of urinary α1 microglobulin versus blood lead 
          by HpyCH4 genotypes 
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      Multiple linear regression (MLR) model with the cross-product of PbB and 
HpyCH4 was subsequently used to check if the slopes of two regression lines were 
statistically different after adjusting for confounders.    
Table 4.17: MLR model of Uα1m_Log for HpyCH4 SNP 
  B 95% CI S. B. t Sig. 
DV: Uα1m_Log    (R2=0.2366)    
HpyCH4 -0.067 (-0.177, 0.043) -0.076 -1.2 0.233 
PbB (μg/dl) 0.018 (0.008, 0.027) 0.865 3.72 <0.001 
HpyCH4 *PbB -0.014 (-0.022, -0.005) -0.746 -3.2 0.002 
DV: dependent variable; B: β coefficient; 95%CI: 95% confidence interval; S. B.: standardized β 
coefficient; Sig.: significance. HpyCH4 is a categorical variable with two categories, HpyCH4 1-1 
& HpyCH4 1-2. HpyCH4 1-1 is the reference goup. The model adjusts for age, sex, BMI and 
exposure duration.  
      In the MLR model of Uα1m_Log, the β coefficient of interaction term between 
HpyCH4 and PbB was significant (P=0.002), suggesting the interaction between the two 
variables (Table 4.17). HpyCH4 polymorphism therefore was shown to be able to change 
the association between PbB and Uα1m, which can be manifested by the difference in the 
β coefficient of PbB for HpyCH4 1-1 and HpyCH4 1-2 genotype group. According to this 
model, the unit increase in PbB would bring about 0.018 Uα1m_Log (anti-log 1.042 
mg/gCr) for HpyCH4 1-1 subjects whereas it would bring about only 0.004 Uα1m_Log 
(anti-log 1.009 mg/gCr) for HpyCH4 1-2 carriers.  
      The model demonstrated that the effect of PbB on Uα1m depended on the 
HpyCH4 status, in other words, HpyCH4 could modify the function of PbB on Uα1m. The 
effect modification of HpyCH4 SNP was illustrated in the following figure.  
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<Y, predicted Uα1m_log; X, blood lead. ○: Blue loop represents points specified by value pair of PbB and 
Uα1m_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of PbB 
and Uα1m _Log for HpyCH4 1-2 heterozygotes> 
      In figure 4.10, the negative linearity of HpyCH4 1-2 regression line displayed in 
figure 5.9 disappeared. The regression line for HpyCH4 1-1 (β= 0.018) subjects was 
steeper than the line for HpyCH4 1-2 (β=0.004) individuals. Actually, it seemed that blood 
lead puts little effect on the concentration of Uα1m as the line for HpyCH4 1-2 group was 




Figure 4.10: Regression lines of urinary α1 microglobulin versus blood lead 
by HpyCH4 genotypes after adjustment for age, exposure 
duration, gender and BMI. 
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4.5.1.2.  Urinary β2 microglobulin (Uβ2m) 
      PbB was the only significant predictor for Uβ2m. Its HpyCH4-specific correlation 
to Uβ2m was illustrated in Figure 4.11.  

























<Y, original values of Uβ2m_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and Uβ2m_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and Uβ2m_Log for HpyCH4 1-2 heterozygotes> 
      Figure 4.11 suggested that the Uβ2m-PbB relationship for wild type homozygotes 
was different from that for variant carriers. HpyCH4 1-2 subjects were shown to be 
resistant to lead toxicity with regard to urinary concentration of β2 microglobulin. The 
significance of the comparison was subjected to MLR analysis.  
Table 4.18: MLR model of Uβ2m_Log for HpyCH4 SNP 
  B 95% CI S. B t Sig. 
DV: Uβ2m_Log    (R2=0.1417)    
HpyCH4 0.047 (-0.103, 0.197) 0.042 0.62 0.537 
PbB (μg/dl) 0.029 (0.016, 0.042) 1.076 4.37 <0.001 
PbB*HpyCH4  -0.024 (-0.035, -0.012) -1.017 -4.11 <0.001 
DV: dependent variable; B: β coefficient; 95%CI: 95% confidence interval; S. B.: standardized β coefficient; 
Sig.: significance. The model adjusts for age, sex, BMI and exposure duration. HpyCH4 is a categorical 
variable with two categories, HpyCH4 1-1 & HpyCH4 1-2. HpyCH4 1-1 is the reference group.    
Figure 4.11: Regression lines of urinary β2 microglobulin versus blood 
lead by HpyCH4 genotypes  
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      In the MLR model of Uβ2m_Log, blood lead was an important predictor even after 
adjustment. The β coefficient of PbB was 0.029 for HpyCH4 1-1 subjects. Because the β 
coefficient of HpyCH4*PbB was significant (p=0.002), it was allowed to calculate the 
corresponding β coefficient for HpyCH4 1-2 subjects, which is the sum of Bs of PbB and 
the interaction term 0.005=(0.029+(-0.024)). The B of PbB*HpyCH4, representing the 
difference in β coefficients of PbB by HpyCH4 genotype, was of statistical significance 
(P=0.002). By discovering the difference in the β coefficient of PbB between HpyCH4 1-1 
and HpyCH4 1-2 genotype groups, the model demonstrated that HpyCH4 polymorphism 
could change the association between PbB and Uα1m. The effect of PbB on Uα1m 
depended on the HpyCH4 status, in other words, HpyCH4 modified the effect of lead 
toxicity to kidneys. The increment of Uβ2m corresponding to unit increase of PbB (1 
μg/dl) was 1.069 μg/gCr and 1.012 μg/gCr for HpyCH4 1-1 and HpyCH4 1-2 respectively. 
The effect modification of HpyCH4 SNP was illustrated in the following figure (Figure 
4.12).  
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<Y, predicted values of Uβ2m_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and Uβ2m_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and Uβ2m_Log for HpyCH4 1-2 heterozygotes> 
      The figure 5.12 clearly showed that the regression line for HpyCH4 1-1 subjects 
was steeper than the line for HpyCH4 1-2 people. The two lines intersected at the PbB 
around 25 μg/dl. At the PbB ranging from 25 μg/dl upward, the predicted Uβ2m for 
HpyCH4-2 carriers was constantly higher than the predicted value of Uβ2m for 
HpyCH4-1 homozygotes. The opposite came out when PbB was less than 25 μg/dl.  
4.5.1.3.  Urinary retinol binding protein (URBP) 
 
      To compare the URBP-PbB relationship between HpyCH4 1-1 and HpyCH4 1-2 
groups, the regression lines were drawn with least square method in the scatter plot of 
URBP versus PbB. The comparison was illustrated in the figure below (Figure 4.13).  
Figure 4.12: Regression lines of urinary β2 microglobulin versus blood lead by 
HpyCH4 genotypes after adjustment for age, exposure duration, 
gender and BMI.  
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<Y, original values of URBP_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and URBP_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and URBP_Log for HpyCH4 1-2 heterozygotes> 
      The line for HpyCH4 wild type homozygotes suggested an upward trend of URBP 
to PbB whereas the line for HpyCH4 variant suggested a downward trend. The seeming 
protective effect of PbB in variant allele group could be ascribed to the effect of 
confounders. The stepwise regression analysis was conducted to analyze this difference. 
Table 4.19: MLR model of URBP_Log for HpyCH4 SNP 
  B 95% CI S. B t Sig. 
DV: URBP_Log   (R2=0.1473)    
HpyCH4 -0.02 (-0.140, 0.100) -0.022 -0.33 0.742 
PbB (μg/dl) 0.016 (0.006, 0.027) 0.772 3.14 0.002 
PbB*HpyCH4 -0.012 (-0.022, -0.003) -0.66 -2.68 0.008 
DV: dependent variable; B: β coefficient; 95%CI: 95% confidence interval; S. B.: standardized β 
coefficient; Sig.: significance. The model adjusts for age, sex, BMI and exposure duration. 
HpyCH4 is a categorical variable with two categories, HpyCH4 1-1 & HpyCH4 1-2. HpyCH4 1-1 
is the reference goup.  
        The MLR model found that blood lead was a significant predictor for URBP 
Figure 4.13: Regression lines of retinol binding protein versus blood 
lead by HpyCH4 genotypes  
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after adjustment for confounders. The model also found a significant interaction between 
PbB and HpyCH4 SNP, which means HpyCH4 polymorphism could modify the toxicity 
of PbB on URBP. The β coefficient of PbB, which also represents the size of the lead’s 
effect on URBP in HpyCH4 1-1 group, was 0.016 with a significant P value of 0.002. 
According to the model, the corresponding β coefficient in HpyCH4 1-2 group should be 
the sum of Bs for PbB and PbB*HpyCH4, 0.004=0.016 + (-0.012). The β coefficient of 
the cross-product term was actually the difference by genotype in β coefficients of PbB 
which had a statistical significance (P=0.008). The discovery of the significant difference 
in Bs of PbB between HpyCH4 genotypes demonstrated that HpyCH4 polymorphism 
could change the linearity between URBP and PbB. The function of PbB on Uα1m was 
related to the subject’s HpyCH4 status. So HpyCH4 polymorphism modified the effect of 
PbB. The increment of URBP corresponding to 1 μg/dl of PbB was 0.016 (anti_log is 
1.038 mg/gCr), and 0.004 (anti_log is 1.009 mg/gCr) for HpyCH4 1-1 and HpyCH4 1-2 
subjects respectively.  
 
     The effect modification of HpyCH4 SNP was illustrated in figure 4.14. 
 





<Y, predicted values of URBP_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and URBP_Log for HpyCH4 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and URBP_Log for HpyCH4 1-2 heterozygotes> 
 
      The points closely gathered along the two regression line. The line for HpyCH4 
1-1 subjects was steeper than the line for HpyCH4 1-2 people. Like Uα1m and Uβ2m, The 
two lines crossed at the PbB around 25 μg/dl. When PbB was more than 25 μg/dl, the 
predicted values of URBP for HpyCH4-2 carriers were higher than the same predicted 
values for HpyCH4-1 homozygotes. The opposite direction existed when PbB was less 
than 25 μg/dl.  
 

























Figure 4.14: Regression lines of urinary retinol binding protein versus blood lead 
by HpyCH4 genotypes after adjustment for age, sex, exposure 
duration and BMI        
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4.5.2   Rsa SNP in Exon 4 
      The Rsa SNP has 3 genotype groups, Rsa 1-1, Rsa 1-2 and Rsa 2-2. The following 
graph showed the comparison of PbB-ALAU_Log linear relationship among Rsa 
genotype groups before adjusting for confounders.   
<Y, original values of ALAU_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and ALAU_Log for Rsa 1-1 homozygotes. ＋: Green cross represents points specified by value pair of PbB 
and ALAU_Log for Rsa 1-2 heterozygotes. : Grey asterisk represents points specified by value pair of 
PbB and ALAU_Log for Rsa 2-2 homozygotes> 
  
      In the scatter plot of ALAU VS PbB (Figure 4.15), it was indicated that the 
regression lines for Rsa1-1, Rsa1-2 and Rsa2-2 genotypes were different. The line for Rsa 
1-1 stayed far from Rsa 1-2 and Rsa 2-2 regression lines, but the latter lines were close to 
each other. The line of wild type homozygotes was steeper than the other two lines.  
      The MLR model was successively built to check the significance of the difference 






















Figure 4.15: Regression lines of urinary amino levulinic acid versus 
blood lead by Rsa genotypes 
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of slopes. ALAU serveed as dependent variable and PbB was the main independent 
variable in the model. Rsa entered the model as two dummy variables with Rsa 1-1 being 
the reference category. The cross-products of PbB and the dummy variables were used to 
explore the interaction between PbB and Rsa polymorphism. Just like the models built in 
the previous analysis, confounders selected were age, sex, BMI and exposure duration.  
Table 4.20: MLR model of ALAU_Log for Rsa SNP 
  B 95% CI S. B.  t Sig. 
DV: ALAU_Log  (R2= 0.424)    
Rsa 1-2 -0.042 (-0.091, 0.007)  -0.111 -1.689 0.093 
Rsa 2-2 -0.038 (-0.092, 0.016)  -0.092 -1.377 0.17 
PbB (μg/dl) 0.013 (0.010, 0.016)  0.928 7.994 ＜0.001 
PbB*Rsa 1-2 -0.005 (-0.008, -0.001)  -0.233 -2.464 0.015 
PbB*Rsa 2-2 -0.005 (-0.009, -0.001) -0.21 -2.523 0.012 
DV: dependent variable; B: β coefficient; 95%CI: 95% confidence interval; S. B.: standardized β 
coefficient; Sig.: significance. The model adjusts for age, sex, BMI and exposure duration. Rsa is a 
categorical variable with three categories, Rsa 1-1, Rsa 1-2 and Rsa 2-2. Rsa 1-1 is the reference 
group.    
 
      After adjustment, blood lead was still a significant predictor for ALAU (P<0.001). 
The two dummy variables were not significant. The model found the effect modification 
of Rsa polymorphism on the association of PbB with ALAU shown by the significant 
cross-product terms, PbB*Rsa 1-2 (p=0.015) and PbB*Rsa 2-2 (p=0.012), indicating the 
interactions between PbB and Rsa (Table 4.20).  
      The modifying effect of Rsa was manifested by the differences between β 
coefficients of PbB for each Rsa genotype, which were the Bs of PbB*Rsa1-2 and 
PbB*Rsa2-2. The B of PbB*Rsa1-2 represented the difference in β coefficient of PbB 
between Rsa 1-1 and Rsa 1-2. The B of PbB*Rsa 2-2 represented the difference in β 
coefficient between Rsa 1-1 and Rsa 2-2. The B of PbB (0.013) in above table represented 
the effect size of lead on ALAU in Rsa 1-1 group. The corresponding coefficient in Rsa 
1-2 group was 0.008, the sum of Bs for PbB (0.013) and PbB*Rsa 1-2 (-0.005). The effect 
size of PbB on ALAU for Rsa 2-2 group was also found to be 0.008, the sum of Bs for 
PbB (0.013) and PbB*Rsa 2-2 (-0.005). 
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      The model demonstrated that PbB operated differently in Rsa 1-1 group relative to 
Rsa 1-2 and Rsa 2-2 groups. Thus the function of PbB on ALAU was Rsa 
genotype-specific, in other words, Rsa polymorphism modified the toxicity of lead. But 
for the groups with Rsa-2 allele, PbB took the same effect because its β coefficient was the 
same for Rsa 1-2 and Rsa 2-2 groups.  
      This model predicted an increment of 1.03 mg/gCr in ALAU when PbB increased 
by 1 μg/dl for Rsa 1-1 subjects. The model predicted an increment of only 1.019 mg/gCr 
in ALAU for Rsa 1-2 and Rsa 2-2 subjects respectively with the same increase in PbB. 





< Y, predicted values of ALAU_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and ALAU_Log for Rsa 1-1 homozygotes. ＋: Green cross represents points specified by value pair of PbB 
and ALAU_Log for Rsa 1-2 heterozygotes. : Grey asterisk represents points specified by value pair of 
PbB and ALAU_Log for Rsa 2-2 homozygotes> 
Figure 4.16: Regression lines of urinary amino levulinic acid versus blood 
lead by Rsa genotypes after adjustment for age, sex, exposure 
duration and BMI             
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      Based on the MLR model, the regression lines were generated in Figure 4.16. They 
described the linear relationship between PbB and ALAU in each Rsa genotype group 
after adjustment for confounders. Regression lines fit to the points better and the 
differences between them are more pronounced. Figure 4.16 showed the same pattern for 
comparisons of regression lines as the pattern in Figure 4.15. The line for Rsa 1-1 stayed 
away from the lines for Rsa 1-2 and Rsa 2-2 group. Rsa 1-1 line also had a bigger slope 
than the other two lines. The regression lines for Rsa-2 carriers were similar and nearly 
overlapped.  
      The three regression lines intersected at the PbB around 12 μg/dl. This suggested 
that at the PbB range less than 12 μg/dl, the predicted ALAU values for Rsa-2 carriers 
would be lower than the predicted values for Rsa-1 homozygotes. The opposite 
comparison existed at the PbB value more than 12 μg/dl.  
4.5.3   Rsa SNP in Exon 5 (Rsa39) 
      The effect modification of Rsa39 in exon 5 was observed in relation to ALAU. Just 
like Rsa SNP in exon 4, Rsa SNP in exon 5 was classified into 3 subgroups Rsa39 1-1, 
Rsa39 1-2 and Rsa39 2-2. The comparisons of regression lines before adjustment were 
shown in figure 4.17. 
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<Y, original values of ALAU_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and ALAU_Log for Rsa39 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and ALAU_Log for Rsa39 1-2 heterozygotes. : Grey asterisk represents points specified by value 
pair of PbB and ALAU_Log for Rsa39 2-2 homozygotes>  
 
      The Figure 4.17 suggested the different linearity between ALAU and PbB in each 
genotype group. The regression line for Rsa39 2-2 had opposite direction to Rsa39 1-1 
and Rsa39 1-2 regression lines. The lines for Rsa-1 homozygotes and Ras39 1-2 
heterozygotes were parallel to each other.   
      The MLR model was subsequently built to check the significance of the difference 
between regression lines. ALAU served as dependent variable and PbB was the major 
independent variable. Rsa39 SNP entered the MLR model as two dummy variables with 
Rsa39 1-1 being the reference category. The cross-products of PbB and two dummy 
variables were used to explore the interaction between PbB and Rsa39 polymorphism. The 
model adjusted for age, sex, BMI and exposure duration.  
         
Figure 4.17: Regression lines of urinary amino levulinic acid versus 
blood lead by Rsa39 genotypes  
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Table 4.21: MLR model of ALAU_Log for Rsa39 SNP 
        B 95% CI S. B. t Sig. 
DV: ALAU_Log  ( R2= 0.427)     
RSA39 1-2 -0.006 (-0.055, 0.044) -0.015 -0.222 0.824 
RSA39 2-2 -0.033 (-0.087, 0.022) -0.079 -1.183 0.238 
PbB (μg/dl) 0.013 (0.009, 0.016) 0.903 7.398 <0.001 
PbB*Rsa39 1-2 -0.003 (-0.007, 0.001) -0.137 -1.434 0.153 
PbB*Rsa39 2-2 -0.006 (-0.01, -0.002) -0.248 -2.772 0.006 
DV: dependent variable; B: β coefficient; 95%CI: 95% confidence interval; S. B.: standardized β 
coefficient; Sig.: significance. The model adjusts for age, sex, BMI and exposure duration. Rsa39 
is a categorical variable with three categories, Rsa39 1-1, Rsa39 1-2 and Rsa39 2-2. Rsa39 1-1 is 
the reference group.    
      After adjustment, blood lead was still a significant predictor for ALAU (P<0.001). 
The two dummy variables were not significant. The model found the effect modification 
of Rsa39 SNP on the association of PbB with ALAU shown by the significant 
cross-product term of PbB*Rsa39 2-2, indicating the interactions between PbB and Rsa39 
(p=0.006). PbB*Rsa39 2-2 displayed the significant difference between β coefficients of 
PbB for Rsa39 1-1 and Rsa39 2-2 subjects. The B of PbB (0.013) in above table 
represented the effect size of lead on ALAU in Rsa39 1-1 group. The corresponding 
coefficient in Rsa39 2-2 group was 0.007, the sum of Bs for PbB (0.013) and PbB*Rsa39 
2-2 (-0.006). Because the B of PbB*Rsa39 1-2 was not significant (p=0.153), there was no 
difference in ALAU-PbB linear relation between Rsa39 1-1 and Rsa39 1-2. 
      By discovering the differences in Bs of PbB between Rsa39 1-1 and Rsa39 2-2, the 
model demonstrated that PbB worked differently in Rsa39 1-1 group relative to Rsa39 2-2 
groups. Thus the function of PbB on ALAU was related to Rsa39 genotype, that is, Rsa39 
polymorphism modified the toxicity of lead.  
      This model predicted an increment of 1.03 mg/gCr in ALAU when PbB increased 
by 1 μg/dl for Rsa39 1-1 subjects. The model predicted an increment of 1.016 mg/gCr in 
ALAU for Rsa39 2-2 subjects with the same increase in PbB. 
      The effect modification of Rsa39 polymorphism was illustrated in Figure 4.18.  
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<Y, predicted values of ALAU_Log; X, PbB. ○: Blue loop represents points specified by value pair of PbB 
and ALAU_Log for Rsa39 1-1 homozygotes. ＋: Green cross represents points specified by value pair of 
PbB and ALAU _Log for Rsa39 1-2 heterozygotes. : Grey asterisk represents points specified by value 
pair of PbB and ALAU _Log for Rsa39 2-2 homozygotes> 
 
      The regression lines specified by MLR model were constructed in Figure 4.18. 
Controlling over the effect of confounders, the better fit to the data was obtained for each 
regression line and the differences between them were pronounced. Figure 4.18 showed 
the same pattern for comparisons of regression lines as the pattern in Figure 4.17. The line 
for Rsa39 1-1 lay away from the line of Rsa39 2-2 group. Rsa 1-2 regression line lay in 
between. The line for Rsa39 1-1 had the biggest slope among 3 lines.  
      Just like Rsa SNP in exon 4, the regression lines intersected at the PbB around 12 
μg/dl. The predicted ALAU for Rsa39 2-2 carriers were constantly lower than the 
predicted values for Rsa39-1 homozygotes when PbB was less than 12 μg/dl. The opposite 
comparison existed at when PbB was greater than 12 μg/dl.  
Figure 4.18: Regression lines of urinary amino levulinic acid versus blood lead 
by Rsa39 genotypes after adjustment for age, sex, exposure 
duration and BMI             
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      In summary, this project reported the distribution of 6 ALAD SNPs. Apart from 
Msp in exon 4, the allele and genotype frequencies were also reported for Rsa in exon 4 
and exon 5 (Rsa39), HpyCH4 in intron 6, HpyIV for intron 6 and Sau3A in intron 12. The 
significant positive correlations were found between PbB and Uα1m, Uβ2m, URBP, 
TNAG and ALAU. PbB was the significant predictor in the stepwise linear regression 
models of these outcome variables. The comparisons of mean PbB and renal parameters 
between genotype subgroups in each SNP did not obtain significant results except that 
Rsa39 2-2 had higher PbB than Rsa39 1-1 and Rsa39 1-2 . HpyCH4 SNP could modify 
the relationship between PbB and Uα1m, Uβ2m and URBP. Rsa and Rsa39 SNPs could 
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CHAPTER FIVE 
DISCUSSION 
5.1    DISTRIBUTIONS OF ALAD POLYMORPHISMS  
      This is the first report on ALAD polymorphism distribution in Vietnamese. It is 
also the first epidemiological study to examine 6 ALAD SNPs in one single study as well 
as their association with the health effect of lead.  
      With regard to the traditional ALAD polymorphism, ALAD 1-1 homozygotes 
account for 92.6 % of the 244 people population with Msp measurement. In total, 6.6% of 
people are ALAD 1-2 and there are only 8% subjects homozygous for ALAD-2 allele. The 
frequency of wild type allele is calculated as 0.959 and the frequency of variant is 0.041. 
The allele frequencies of alleles are similar to those found in studies in china (Zheng et al., 
2001a; Shen et al., 2001), Taiwan (Hsieh et al., 2000)and South Korean (Kim et al., 2004).   
      The genotype and allele distributions of HpyCH4, HpyIV, Rsa, Rsa39 and Sau3A 
SNPs were summarized in Table 4.5. This study is the first one which measured these new 
SNPs in a population randomly selected. The SNP distributions can serve as reference for 
future studies.    
5.2 EARLY BIOLOGICAL EFFECT FOR LEAD INDUCED 
NEPHROPATHY   
      Researchers in the field of lead study have long been attempting to identify the 
specific EBEs for renal dysfunction in response to lead exposure. The identification of 
EBEs can greatly advance the lead study and reduce the possibility of wrong inference due 
to misuse of renal parameters.  
      The classical renal function indices measuring the filtration function of glomeruli 
are insensitive at the early stage of lead induced nephropathy because kidneys have large 
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reserve of the glomeruli function. It was suggested that more than 60% of kidney function 
would need to be impaired before parameters CCr, SCr, and BUN show some abnormality 
(Loghman-Adham, 1997; Goyer, 1993) . The alternative parameters in consideration are 
urinary or serum concentration of low molecular weight proteins (α1m, β2m, RBP) or 
enzymes (NAG) that would be increased when kidneys are injured. These parameters are 
expected to be more sensitive and specific to lead induced renal damage compared to the 
classical renal parameters. However, the current evidences didn’t prove that the 
parameters based on the concentration of renal proteins are superior to classical renal 
parameters. Many studies are under way in order to evaluate the validity of these renal 
protein indices.  
5.2.1   Evaluation of Uα1m, Uβ2m, URBP and TNAG 
      This study applied stepwise regression analysis to evaluate the variables of age, 
gender, BMI, exposure duration and blood lead that can affect renal function. The 
stepwise regression models demonstrated the significant positive relationships between 
PbB and Uα1m, Uβ2m, URBP as well as TNAG. Among the 4 renal tests, TNAG is 
probably the most sensitive index. The two significant predictors (PbB, Exposure 
Duration) selected by the model are both the measurements of exposure level. The model 
accounts for 22.7% of the variance of TNAG and PbB is the first predictor selected with a 
larger β coefficient than exposure duration (Table 4.9). PbB is the only significant variable 
in the model of Uβ2m (Table 4.7). In the models of Uα1m, Uβ2m and URBP, PbB 
narrowly achieved significance with mild effect size (Table 4.6, 4.7, 4.8). These models 
confirmed the dose-effect relationships between PbB and these renal variables after 
controlling for potential confounders.  
      The isolated dose-effect relationship between PbB and urinary concentration of 
LMW proteins or TNAG have been reported (Verberk et al., 1996; Bernard and Lauwerys, 
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1996). This study found significant relationships about Uα1m, Uβ2m, URBP and TNAG 
in the stepwise regression models. Since PbB is an index of recent lead exposure for the 
past a few weeks (Snee, 1982; Bert et al., 1989), its correlations with renal tests should 
imply that the increased values of Uα1m, Uβ2m, URBP and TNAG mainly are the result 
of recent lead exposure rather than the lead deposit in bone over time. Taken altogether, 
urinary concentrations of LMW protein and enzymes are good EBEs for lead induced 
renal compromise. The findings offer more credibility to the later results regarding the 
modifying effect of ALAD polymorphism.   
      Lead studies in the past three decades failed to identify the renal EBEs for lead 
toxicity. Even an integrated database for the assessment of biomarkers detecting 
nephron-toxicity can only suggest that TNAG, intestinal alkaline phosphatase (IAP), brush 
border antigen and urinary LMW proteins are generally most sensitive renal tests for the 
early detection of nephropathy (Taylor et al., 1997). After all, the toxic effect of lead 
depends on which parts of the kidney it affects and the intensity of the exposure. Thus 
there may not be universal EBEs for lead toxicity. Applying these renal functions in 
special combination could be a way out, as suggested by some authors. Pergande et al 
(1994) have suggested that for lead-induced tubular changes, Uα1m in conjunction with 
TNAG are useful in the early detection. 
5.2.2   Evaluation of Sα1m and Sβ2m  
      Sα1m and Sβ2m were not found significantly correlated to blood lead. The 
stepwise regression models displayed that only demographic variables are the significant 
predictors for Sα1m and Sβ2m. This is not surprising as no studies investigating the 
correlation of PbB to Sα1m reported any significant results (Chia et al., 1995c; Taylor et 
al., 1997; Verberk et al., 1996). In the study on lead workers conducted in 1993, the mean 
Sα1m level remained nearly constant across 5 groups classified by mean blood lead 
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ranging from 3.4 μg/dl to 9.1 μg/dl. The mean of Sα1m for individual PbB group is similar 
to that measured in general population (2.1 mg/dl) (Endo et al., 1993). Just like Sα1m, 
Sβ2m didn’t show any significant correlation with PbB in most studies(Staessen et al., 
1992; Taylor et al., 1997; Roels et al., 1999).   
      As mentioned in chapter II, the serum concentrations of α1m and β2m have little 
relevance to renal function. The level of Sα1m is mainly decided by its production 
because α1m is easily filtered into urine and only a small percentage of it is reabsorbed 
back into blood. The serum concentration of β2 microglobulin is not specific to renal 
disorders, for it increases in inflammatory reactions and in active chronic lymphocytic 
leukemia in which there is increased lymphocyte turnover (Tolkoff-Rubin et al., 1988). 
This study did not recommend Sα1m and Sβ2m as EBEs in lead study and thus their 
relationship with ALAD polymorphisms proteins will not be discussed further. 
5.3    EFFECT OF ALAD POLYMORPHISMS  
5.3.1   Msp SNP in Exon 4  
      Previous studies using BUN, SCr and CCr as outcome variables indicated that 
ALAD-2 allele was the at-risk allele with regard to renal toxicity of lead (Smith et al., 
1995; Weaver et al., 2003b; Wu et al., 2003). In this study, the traditional ALAD 
polymorphism did not show any significant effect on blood lead and renal parameters, or 
effect modification on the lead toxicity to kidneys. Although the significant differences 
were suggested in the crude comparisons of ALAU (p=0.058) and PbB (p=0.084) (Table 
4.11). They became insignificant after the adjustment. Our results therefore could not 
ascertain which allele is the susceptible one.  
      Two studies choosing renal LME or lysosomes concentrations as outcome 
parameters failed to get some significant findings (Bergdahl et al., 1997; Weaver et al., 
2003b). In the study by Weaver et al (2003), TNAG and URBP were not significantly 
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different by ALAD genotype while ALAD polymorphism modified the lead effect on 
BUN, SCr and calculated CCr. The comparisons of Sβ2m, Uβ2m and TNAG between 
ALAD 1-1 homozygotes and ALAD-2 carriers turned out insignificant (Bergdahl et al., 
1997). The results from our project were consistent to the above-mentioned studies. 
5.3.2   Newer ALAD Polymorphisms and Renal Functions 
      Although, the gene-environment interaction was not demonstrated by the 
traditional ALAD polymorphism, the newly identified SNPs, one intronic polymorphisms 
(HpyCH4 SNP in intron 6) and two silent exonic polymorphisms (Rsa SNP in exon 4 and 
Rsa39 SNP in exon 5), displayed their modifying effect on lead toxicity with regard to 
certain outcome parameters.  HpyCH4 ALAD polymorphism modifies the association of 
PbB with Uα1m, Uβ2m and URBP. For individuals with HpyCH4-2 allele, 1 μg/dl PbB 
will contribute 1.009 mg/gCr Uα1m, 1.012 μg/gCr Uβ2m and 1.009 mg/gCr URBP. 
However, for people with HpyCH4 1-1 genotype, 1μg/dl PbB will bring about 1.042 
mg/gCr, Uα1m, 1.069 mg/gCr Uβ2m and 1.038 mg/gCr URBP. The subjects with 
HpyCH4 1-1 genotype and HpyCH4 1-2 genotype respond differently to lead exertion. 
The renal outcomes are worse for subjects homozygous for wild type allele. HpyCH4-1 is 
the risky allele that confers the more susceptibility to lead exposure. 
      For the classical polymorphism, Msp SNP in exon 4, the allele-specific 
susceptibility to lead has been attributed to the differential binding abilities of the ALAD 
isozymes. However, being located in the intron region of the ALAD gene, technically 
HpyCH4 SNP does not have any protein coding functions involved. Its influence on the 
ALAD enzyme sound unreasonable. It was said that some DNA behave as exons when 
expressed by one pathway, but as introns when expressed by another pathway. Both 
pathways can operate simultaneously, resulting in greater protein product variety. As such, 
the ALAD enzyme encoded by HpyCH4 1-1 and HpyCH4 1-2 could have been produced 
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through one of such pathways (George and David, 1998). Regulatory functions of introns 
may involve controlling gene activity in different developmental stages or responding to 
immediate biological needs by controlling local gene expressions. This function of introns 
could occur if, as one theory indicates, exons code for a domain, a polypeptide unit that 
has a discreet function such as binding to a membrane, or to the catalytic site of an 
enzyme or serving as a structural unit of a protein (Jerry, 2001). Recent work has 
demonstrated that intronic mutations can have functional consequences in some genes like 
p53 (Lehman et al., 2000). Likewise intronic mutations may also have functional 
consequences in the ALAD genes.  
      One study, which examined Msp polymorphism in intron 2, has reported that 
polymorphisms located in introns can be associated with lead toxicity with variant 
subjects associated with decreased bone lead concentration (Kamel et al. 2003).  
      Rsa SNP in exon 4 and exon 5 (Rsa39) were both found acting on the relationship 
between PbB and ALAU. The first polymorphism had a strong variant allele, Rsa-2 allele. 
When PbB increased by 1 μg/dl, ALAU only increased by 1.019 mg/gCr in Rsa 1-2/2-2 
subjects whereas ALAU increased by 1.03 mg/gCr in Rsa 1-1 subjects. The Rsa39 
polymorphism also had a strong Rsa39-2 allele except that 2 copies of variant were 
required to show the protective effect. When PbB increased by 1 μg/dl, ALAU increased 
1.03 mg/gCr in Rsa39 1-1 homozygotes whereas ALAU only increased 1.016 mg/gCr in 
subjects homozygous for Rsa39-2. In Rsa39 1-2 heterozygotes, the effect of PbB on 
ALAU was in between and was of no significance (p=0.153).  
      Rsa RFLP is a silent polymorphism which is not able to change the sequence of 
amino acid in ALAD protein. The working mechanism underneath may be the result of its 
effect on pre-mRNA splicing because coding-region polymorphisms might cause 
phenotypic variability by influencing splicing accuracy or efficiency (Cartegni et al., 
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2002). The mechanisms explaining the effect of intronic polymorphisms may also be 
applicable to the silent exonic polymorphisms.  
5.4    GENERAL LINEAR MODEL AND MULTIPLE REGRESSION  
      Most of the studies published so far did not examine the contribution of 
individuals’ lead levels to the outcomes by separate genotypes. Comparing the mean of the 
measured outcomes in population with the different genotypes may give too crude an 
estimate of any association. In fact, the findings of this study showed the inadequacy of 
just comparing means. If one examined the effect of ALAD polymorphism based on the 
comparisons of means, the interpretation of the findings could be different. Among 6 
SNPs investigated, only Rsa39 showed significant differences in comparisons of PbB after 
adjustment for confounders through GLM. Blood lead was significantly higher for Rsa39 
2-2 homozygotes compared to Rsa39 1-1 (p=0.032) (Table 4.16). On the basis of the GLM 
results, one would come to a conclusion that Rsa39-2 variant is the susceptible allele to 
lead exposure and other polymorphisms did not exhibit any effect on lead toxicity. But if 
one went further to explore the modifying effect of these ALAD polymorphisms, a 
completely different picture emerged. Rsa39-2 and Rsa-2 alleles became the resistant 
allele because of the smaller slopes of PbB in the regression models of renal parameters 
on blood lead for each genotype group (Table 4.20, Figure 4.16, Table 4.21, Figure 4.18). 
HpyCH4 SNP too appeared to be able to alter the lead’s toxicity to Uα1m, Uβ2m and 
URBP with HpyCH4-1 being the risky allele (Table 4.17, 4.18 & 4.19, Figure 4.10, 4.12 
& 4.14). The susceptibility is shown by a greater increment of renal outcomes in response 
to a unit increase of blood lead.  
      It has been noticed recently that the different conclusions can be inferred from the 
same project if different statistical methods are used. Sometimes the results from two 
methods were too confusing to make a confirmative conclusion. Wu et al (2003) found the 
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evidence of a significant interaction of tibia lead with ALAD genotype regarding serum 
creatinine as an outcome. ALAD-2 allele should be considered the susceptible allele 
because ALAD 1-2/2-2 workers would have higher SCr with 1 μg/g increase in Pb-Tibia. 
However, comparing SCr by ALAD genotype did not figure out the risky allele with 
insignificant P value (p=0.222). This project also exhibited that the inference from GLM 
analysis would be disparate from the inference of regression models. This project 
suggested that the multiple regression aiming at effect modification should be preferred.  
5.5    HEALTHY WORKER EFFECT  
      In this study, it is possible that individuals with certain ALAD polymorphisms may 
be more susceptible to effect of lead toxicity on the renal system and thus would have 
been excluded from the workforce even before this study was conducted (“healthy 
workers effect”). But these susceptible workers will need to have obvious clinical renal 
diseases to be removed from the workforce. This is first time that factory workers were 
tested with these renal tests. Therefore it is highly unlikely that the influence of “healthy 
worker effect” would be present in this study. In Vietnam, most of the factories are state 
owned; as is this factory. Most workers would stay in a factory and work there all their 
lives (as can be seen by the long exposure history, Table 4.1). Schwartz et al., (1995) 
reported difference in the Msp ALAD genotypes frequencies among the 3 lead factories 
with different lead exposure. They postulated that workers with the more susceptible 
ALAD genotype may move to a lower lead exposed job. Conversely workers with the 
protective ALAD genotype may stay on as they have fewer symptoms even in higher 
exposure areas. We are unable to study this possible “population stratification” bias as the 
workers were rotated through the different departments/ section in the factory depending 
on the job schedule and manpower requirement.  
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5.6    STRATIFICATION OF SAMPLE   
      In figures 4.10, 4.12 and 4.14 which plot the linear relations between PbB and 
renal parameters, we were able to determine the blood lead level at the intersection point 
of two regression lines for HpyCH4 1-1 and HpyCH4 1-2, which is around 25 μg/dl. For 
subjects with PbB less than 25 μg/dl, HpyCH4 2-2 subjects have higher renal function 
values than HpyCH4 1-1. The opposite is true for subjects with PbB >25 μg/dl. Thus one 
may conclude that HpyCH4-2 is more susceptible when the samples have low lead 
exposure. On the other hand, one might find that HpyCH4-1 is more susceptible when the 
samples have higher exposure (i.e. PbB >25 μg/dl). The intersection point highlighted the 
importance of stratifying the data by PbB when we study the effects of ALAD 
polymorphism. Otherwise, problems would arise and cause biasness in the findings. These 
findings may explain, to some degree, why there were contradicting reports on the 
association between blood lead levels and ALAD alleles in some studies.  
      Most researchers so far believed that the association of ALAD-2 allele with PbB is 
more likely to be captivated at high exposure level (Smith et al., 1995; Suzen et al., 2003; 
Alexander et al., 1998). There appears to be a threshold or artificial value of PbB with 
regard to ALAD polymorphism and its effect on the renal system. Either type of allele can 
be considered susceptible depending on the exposure level to which the selected 
population is exposed. If the sample is not properly stratified by PbB, the heterogeneous 
effect of ALAD polymorphism will result in non-significance.  
      The sensitivity of the outcome variable seems to be able to affect the threshold of 
the blood lead level. For Uα1m, Uβ2m and URBP, the value of PbB is 25 μg/dl, and for 
ALAU it is 12 μg/dl. The figures (4.10, 4.12 & 4.14) displaying the comparisons of 
regression lines for HpyCH4 genotypes all found that PbB is 25 μg/dl at the intersection 
point. When ALAU is treated as the dependent variable, the threshold PbB is 12 μg/dl 
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exhibited in figure 4.16 and 4.18. In terms of the sensitivity to PbB, ALAU as an outcome 
is much more sensitive than renal function indices.  
5.7    LIMITATIONS 
5.7.1   Lack of Measurement of Classical Renal Function Parameters  
      This study supports the use of the concentration of urinary protein and lysosomes 
as EBEs for lead induced nephropathy. But it does not provide evidence that the renal 
parameters selected are superior to the classical renal parameters although all renal indices 
(Uα1m, Uβ2m, URBP, TNAG) were significantly correlated with PbB obtained by 
stepwise regression models. Because the study did not measure classical renal indices, one 
could not compare the utility of new renal parameters with classical renal functions like 
SCr, CCr, and BUN. As a study population consisting of healthy workers, one may assume 
that their renal functions would be normal. Ualb, which can be treated as a classical renal 
function parameter to some extent, was not found to be associated with PbB. This may 
more or less give us some clues of the possible behavior of classical parameters had they 
been measured in our study.   
      So far there were no studies to compare which parameters are better EBEs for 
early renal deterioration specifically induced by lead. Our study at the most is one of the 
studies that provided additional evidence in favor of renal LMW proteins and enzymes.   
5.7.2   Lack of Measurement of Body Lead Burden  
      It has been suggested that cumulative exposure to lead can increase the 
concentration of Uα1m with a dose-response and dose-effect relationship (Chia et al., 
1995). In our study, we are not able to evaluate the contribution of long-term lead 
exposure to renal indices because of the lack of bone lead measurement. This may 
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undermine our conclusion that urinary concentrations of renal proteins are sensitive EBEs 
for recent lead expusure. However, the direct correlations between Pb-Bone and renal 
indices were scarcely reported. Roels et al’s study did not find any difference in Ualb, 
Uβ2m and URBP between exposed workers and controls, in spite that Pb-Tibial in 
exposed group was three fold that of the control group (Roels et al., 1994). During the 
stepwise regression analysis in our study, exposure duration, a substitute for cumulative 
lead index, achieved significance only in the model of Uβ2m. Hence, even though the 
deposited lead may play a part in the variation of renal parameters, the effect would not be 
strong enough to confound the relationships between renal indices and PbB.  
      The Msp SNP in exon 4 has been reported to change the lead partition between 
cortical and trabecular bone (Smith et al., 1995), the release of lead from bone (Hu et al., 
2001), and the lead uptake from blood into skeleton (Fleming et al., 1998). Msp 
polymorphism also appeared to change the threshold of Pb-Patella with regard to serum 
uric acid (Wu et al., 2003). This study is not able to explore the effect of ALAD on the 
toxic dynamics of lead, nor can one reveal whether these polymorphisms can modify the 
effect of long-term lead exposure in relation to renal functions.  
5.7.3   Small Sample Size  
      The sample size of this study could have been large if not due to some missing 
values. The original population of 323 workers gave a response rate of 88.2% to 276. 
After exclusion of the subjects without any genotype measurement, 248 subjects were left.  
      The small response rate may affect the distribution of ALAD polymorphisms, the 
frequencies of allele and genotype. However, the genotype and allele distributions of each 
ALAD SNP followed Hardy-Weinberg Equilibrium, as such, the data of frequencies are 
still representative (Table 4.5).  
      In this project, the loss of data is due to the inadequacy of sample, so that it can be 
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rationally considered a random event irrelevant to renal function, exposure status, blood 
lead and genotype. The prior analysis between subjects with genotype and subjects 
without showed that the two populations are homogenous in terms of the demographic 
characters and exposure status. The problem caused by small sample size that concerns the 
investigators most, a biased sample, does not seem to be present in this study.   
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
6.1    CONCLUSION  
      i> Unlike Cadmium toxicity, the sensitive and specific indices to represent renal 
functions at early stage of lead intoxication are not identified and confirmed yet. The 
successful identification of these variables would be beneficial to researchers and clinical 
practitioner alike. Researchers can use them to explore the possible gene-environment 
interaction in the course of lead exposure. Doctors practicing occupational medicine can 
use them to monitor the deterioration of renal function and provide timely intervention to 
prevent the worsening of the renal function.  
      The concentrations of renal proteins in urine have been recommended as EBEs for 
the past several decades. Epidemiological evidences have yet to confirm that these 
parameters are competent EBEs for renal damage caused by lead.  
      This study successfully demonstrated that Uα1m, Uβ2m, URBP and TNAG are 
valuable EBEs of renal function for lead toxicity, which lays important foundation for 
future research. These variables have been suggested to be applied in combination for the 
early detection of lead-induced tubular changes (Pergande et al., 1994). This study 
provided supportive results for this suggestion. 
      ii> It is the truth that Msp in exon 4 alone can not completely explain the 
confusion why populations with similar lead exposure achieved dramatically different 
health outcomes. Attentions are being paid to other SNPs because they are probably 
capable of taking effect in the way the common ALAD polymorphism does. Kamel et al 
(2003) has reported supportive evidence.  
      In this study the intronic polymorphism HpyCH4 in intron 6 and the nonsense 
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exonic polymorphisms Rsa in exon 4 and exon 5 (Rsa39) demonstrated their modification 
effect on lead toxicity whereas the ordinary Msp polymorphism in exon 4 did not. This 
study suggests that, to study the effect of ALAD polymorphism on lead exposure, other 
ALAD SNPs really need to be considered.  
6.2    RECOMMENDATIONS  
6.2.1   Choosing Appropriate Exposure and Outcome Parameters  
For studies looking at the effect modification of ALAD polymorphism, the choice 
of parameters is a vital issue. The health parameters with confirmed dose-effect and/or 
dose-response relationship with lead exposure indices should be firstly chosen as outcome 
variables. Because for the studies of this type, the aim is to examine if ALAD genotype 
modifies the association of exposure index and outcome index, which is a priori for 
further research on ALAD polymorphism. If the basic cause-effect association is not 
observed, the subsequent analysis for the effect of ALAD polymorphism may lose some 
credibility.  
       On the condition that outcome parameters selected are responsive to cumulative 
lead exposure, picking PbB as exposure index would be a disaster. In the case of lead 
toxicity on kidney, it should be better to use PbB when renal enzymes are chose as 
outcome indices in a population with occupational exposure. For a general population 
with unknown intensity of environmental lead exposure, classical parameters like SCr, 
CCr and SUA may work better and lead concentration in bone should be measured. 
However, it should be best if bone lead, both cortical and trabecular bone are measured in 
the future study. The present belief holds that ALAD polymorphism is effective only if it 
is able to alter the kinetics of lead. Without bone lead measurement, the in-depth analysis 
into lead kinetics is difficult.  
 - 125 - 
6.2.2   Choosing Appropriate Statistical Method  
Statistical method is an influential factor to draw the conclusion. Whether one 
searches for the main effect or modifying effect of ALAD polymorphism determines the 
conclusion on which allele is vulnerable. Searching for effect modification of ALAD 
polymorphism should be favorably recommended for three reasons: 1) it serves the prime 
objective of the ALAD research better; 2) it conforms to biological plausibility 3) it avoids 
the confusion caused by exposure level.  
6.2.3   Investigating Other ALAD Snps or Genes 
            With totally 105 SNPs with ALAD gene, it is highly possible that ALAD 
SNPs other than Msp RFLP in exon 4 can affect lead dynamics the way Msp does. 
Whether intronic or exonic polymorphisms, they are capable of altering biochemical 
property of ALAD enzyme, which potentially contribute to additional susceptibility to 
lead for some people with certain alleles.  
Genetic polymorphisms in other genes, like the one encoding vitamin D receptor 
(VDR) can interact with ALAD polymorphism with regard to human susceptibility. This 
situation calls for the investigation into gene-gene interaction between ALAD and other 
genes affecting lead toxicity.   
6.2.4   Identifying the Thresholds for Lead Toxicity and ALAD Polymorphism 
      The minimal dosage of lead toxic to specific organs like kidney and brain, i.e. the 
threshold, haven not been identified either. Although ever low level of lead exposure is 
found to be harmful without an indication of threshold, for a particular outcome parameter, 
lead has to reach a particular level to cause the abnormal variation of the outcome variable. 
This raises the question of mixed population. If a population consists of subjects with lead 
exposure below the threshold and subjects with lead index above the threshold, the overall 
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analysis will be reduced to non-significance.   
      A threshold of exposure level seems to be suggested for the effect of ALAD 
polymorphism. As we reviewed in chapter TWO, ALAD polymorphism can only be 
effective above a certain level of exposure, as least for the association of higher PbB with 
ALAD-2 allele. What happens when lead exposure below this level? Is there no difference 
between ALAD1-1 homozygotes and ALAD-2 carriers or the other way around? Although 
researchers can avoid this problem statistically by seeking for effect modification other 
than main effect of ALAD polymorphism, it is still of practical use to identify or preclude 
the threshold.  
6.2.5   Follow-up Study  
      Most studies so far are cross sectional study except one (Fleming et al., 1998) that 
offered much more information than others. The association captured at the 
cross-sectional plane need to be substantiated with prospective data. There is need to 
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Appendix Ⅰ 
JOINT PILOT PROJECT 
COEH, MOI, VIETNAM AND COFM, NUS, SINGAPORE 
    ALAD POLYMORPHISM AND HEALTH EFFECTS OF LEAD EXPOSURE      
      
Date of Examination: _________________  Group: Exposed/Unexposed 
 
Current Section: ______________________            
 
1. Personal particulars 
1.1    Name: __________________________________________               
 
1.2    Date of birth: _______  1.3  Age: ________  1.4    Sex: 1. Male    2. Female  
  
1.5    Race: 1. Vietnamese  2. Chinese  3. Others ___________  
 
1.6    Date of joining Factory: _______________________ 
 
2. Personal Habits 
 
2.1      Are you currently smoking cigarettes/pipe? 
      1.  Non-smoker 2.  Cigarettes  3.  Pipe 
 
2.2      For non-smokers: 
        Have you ever smoked cigarettes/pipe in the past? 
            1.  Never  2.  Cigarettes  3.  Pipe 
 
2.3      For current cigarette smokers: 
            How many sticks do you usually smoke per day? __________ sticks 
            At what age did you start smoking? ___________________________ 
 
2.4      For ex-cigarette smokers: 
            How many sticks do you usually smoke per day? ________________ sticks 
            At what age did you start smoking? ___________________________ 
            At what age did you quit smoking? ___________________________ 
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2.5      Do you drink alcohol? 
1) No 
2) Yes, occasional & social drinker 
3) Yes, regular (at least once a week regularly) 
 
3.  Health Status 
 
3.1      What is your present health condition? 
         1. Excellent 2. Good    
           3. Poor. If poor, explain briefly why:_____________ 
 
4. Medical History 
 
4.1      Have you ever been told by your doctor to have: 
1) High blood pressure? 1.  Yes  2.  No   
2) Diabetes mellitus?  1.  Yes  2.  No 
3) Kidney diseases?  1.  Yes  2.  No 
4) Any other medical conditions: 
 
4.2     Have any of your family members (parents/siblings) been told by their doctors to have : 
a) High blood pressure? 1.  Yes  2.  No  3.  Don’t know 
b) Diabetes mellitus?  1.  Yes  2.  No  3.  Don’t know 
c) Kidney diseases?  1.  Yes  2.  No  3.  Don’t know 
 
4.3     Do you have the following symptoms? 
 
a. Recurrent abdominal pain? 1. Yes,  _________ (duration in months) 2. No 
b. Severe headache with fits? 1. Yes,  _________ (duration in months) 2. No  
c. Weakness of the hands and forearms?1. Yes,  ___ (duration in months) 2. No 
 
5. Drug History 
 
5.1       Are you currently on any long term medication?  
 
5.2       For the last two weeks, were you on any of the following medication? 
a) Panadol?   1.  Yes  2.  No 
b) Aspirin/Salicylates  1.  Yes  2.  No 
c) Antibiotics?  1.  Yes  2.  No   
d) Others?________________________________ 
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6.     Occupational History 
 
Were you exposed to  
Date (Year) 
 
Name of Factory/Company 
 
Job Title Lead Cadmium Mercury
      
 
    
7.   Medical Examination 
 
7.1       Height: _______cm          7.2       Weight: _____________ kg 
7.3       Blood pressure: ______________________ 
 
8.   Urine clinistix : 
Blood : _____ Glucose :_____  Protein: _____  pH:__ 
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ALAD   δ-aminolevulinic acid dehydratase  
ALAU    Urinary aminolevulinic acid  
BMI    Body Mass Index  
BUN    Blood urea nitrogen  
CCr   Creatinine clearance 
GLM    General linear model 
K-S test    Kolmogorov-Smirnov test  
MLR     Multiple linear regression 
TNAG       Total urinary N-acetyl-beta-D-glucosaminidase  
Pb     Lead 
PbB    Blood lead  
RFLP    Restriction fragment length polymorphism  
Sα1m   Serum α1-microglobulin  
Sβ2m    Serum β2 microglobulin 
SCr   Serum creatinine  
SNP    Single nucleotide polymorphism  
Uα1m    Urinary α1-microglobulin  
Ualb    Urinary albumin  
Uβ2m    Urinary β2 microglobulin  
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